{"title": "PDF", "author": "PDF", "url": "https://www.samfyc.es/wp-content/uploads/2018/08/AlertaJunio2014.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \n Junio 2014  \n \nSelecci\u00f3n realizada por Antonio Manteca Gonz\u00e1lez  \n \nACADEMIC MEDICINE  \n \nGabel S. Expanding the scope of leadership training in medicine. Acad Med 2014;89:848 -852 [AO,I]  \n24662199  R/C \nEXPANDIR EL \u00c1MBITO DE LAS PR\u00c1CTICAS DE LIDERAZGO EN MEDICINA  \n \nGrace ES, Wenghofer EF, Korinek EJ. Predictors of physician performance on competence assessment: findings from \nCPEP, the Center for Personalized Education for Physicians. Acad Med 2014;89:912 -919 [S,I]  \n24871243   R/C \nPREDICTORE S DEL RENDIMIENTO DEL M\u00c9DICO EN LA VALORACI\u00d3N DE LA COMPETENCIA: HALLAZGOS DEL \nCPEP  \n \nSwendiman RA. Deep listening. Acad Med 2014;89:950 [AO,I]  \n24865836   \nESCUCHA PROFUNDA  \n \nANNALS OF INTERNAL MEDICINE  \n \nvan Hees F, Habbema JD, Meester RG, Lansdorp -Vogelaar I, van Ballegooijen M, Zauber AG. Should colorectal cancer \nscreening be considered in elderly persons without previous screening?: a cost -effectiveness analysis. Ann Intern Med \n2014;160:750 -759 [CE,II]  \n24887616   R/C \n\u00bfSE DEBER\u00cdA CONSIDERAR EL CRIBAJE DE C\u00c1NCER COLORRECTAL EN LAS PERSONAS MAYORES SIN \nCRIBAJE PREVIO?: AN\u00c1LISIS DE RENT ABILIDAD  \n \nAl-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, et al. Rate - and rhythm -control \ntherapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014;160:760 -773 [M,II]  \n24887617    R/C \nTRATAMIENTOS PARA EL CONTROL DEL RITMO Y DE LA FRECUENCIA EN PACIENTES CON FIBRILACI\u00d3N \nAURICULAR: REVISI\u00d3N SISTEM\u00c1TICA  \n \nMoyer VA; U.S. Preventive Services Task Force.  Screening for cognitive impairment in older adults: U.S. Preventive \nServices Task Force recommendation statement. Ann Intern Med 2014;160:791 -797 [M,III]  \n24663815  R/C \nCRIBAJE DEL DETERIORO COGNITIVO EN ANCIANOS: DECLARACI\u00d3N DE RECOMENDACI\u00d3N DEL USPSTF  \n \nClark AV, Landefeld CS. A \"green banana\" worth buying in older age: colorectal cancer screening for persons older than \n75 years without previous screening. Ann Intern Me d 2014;160:804 -805 [AO,I]  \n24887619   \nMERECE LA PENA COMPRAR UN \"PL\u00c1TANO VERDE\" A EDAD AVANZADA: CRIBAJE DEL C\u00c1NCER \nCOLORRECTAL EN PERSONAS DE M\u00c1S DE 75 A\u00d1OS SIN CRIBAJES PREVIOS  \n \nKubo A, Shlager  L, Marks AR, Lakritz D, Beaumont C, Gabellini K, et al. Prevention of vertical transmission of hepatitis \nB: an observational study. Ann Intern Med 2014;160:828 -835 [T,I]  \n24862434   R/C \nPREVENCI\u00d3N DE LA TRANSMISI\u00d3N VERTICAL DE LA HEPATITIS B: ESTUDIO OBSERVACIONAL  \n \nBushnell C, McCullough L. Stroke prevention in women: synopsis of the 2014 American Heart Association/ American \nStroke Association guideline. Ann Intern Med 20 14;160:853 -857 [M,II]  \n24935489   R/C \nPREVENCI\u00d3N DEL ICTUS EN MUJERES: SINOPSIS DE LA GU\u00cdA 2014 DE LA AHA/ASA  \n \nARCHIVOS DE BRONCONEUMOLOGIA  \n \nAlmirall J, Blanquer J, Bello S. Neumon\u00eda adquirida en la comunidad en fumadores. Arch Bronconeumol 2014;50:250 -\n254  [AO,I]  \n24387877  R/C \nNEUMON\u00cdA ADQUIRIDA EN LA COMUNIDAD EN FUMADORES  \n \nATENCION PRIMARIA  \n \nCoira G, Bailon E. La invisibilidad de los cuidados que realizan las mujeres. Aten Primaria 2014;46:271 -272 [AO,I]  \n24947845  \nLA INVISIBILIDAD DE LOS CUIDADOS QUE REALIZAN LAS MUJERES  \n  \n Marzo -Castillejo M. El cribado de c\u00e1ncer de mama. \u00bfDebe seguir todo igual? Aten Primaria 2014;46:273 -275 [AO,II]  \n24947846  \nEL CRIBADO DE C\u00c1NCER DE MAMA. \u00bfDEBE SEGUIR TODO IGUAL?  \n \nGorina M, Limonero JT, Pe\u00f1art X, Jim\u00e9nez J, Gass\u00f3 J. Comparaci\u00f3n de la satisfacci\u00f3n de los usuarios de atenci\u00f3n \ndomiciliaria: modelo integrado vs. modelo dispensarizado. Aten Primaria 2014;46:276 -282 [T, II] \n24768653  R/C \nCOMPARACI\u00d3N DE LA SATISFACCI\u00d3N DE LOS USUARIOS DE ATENCI\u00d3N DOMICILIARIA: MODELO INTEGRADO \nVS. MODELO DISPENSARIZADO  \n \nConsta\u00edn GA, Ricardo C, Rodr\u00edguez -G\u00e1zquez Mde L, Alvarez M, Mar\u00edn C, Agudelo C. Validez y utilidad diagn\u00f3stica de la \nescala EAT -26 para la evaluaci\u00f3n del riesgo de trastornos de la conducta alimentaria en poblaci\u00f3n femenina de \nMedell\u00edn, Colombia. Aten Primaria 2014;46:283 -289 [T,I]  \n24703389  R/C \nVALIDEZ Y UTILIDAD DIAGN\u00d3STICA DE LA ESCALA EAT -26 PARA LA EVALUACI\u00d3N DEL RIESGO DE \nTRASTORNOS DE LA CONDUCTA ALIMENTARIA EN POBLACI\u00d3N FEMENINA DE MEDELL\u00cdN, COL OMBIA  \n \nParodi N, Vill\u00e1n YF, Granados MI, Royuela A. Prescripci\u00f3n potencialmente inapropiada en mayores de 65 a\u00f1os en un \ncentro de salud de atenci\u00f3n primaria. Aten Primaria 2014;46:290 -297 [T,I]  \n24661973  R/C \nPRESCRIPCI\u00d3N POTENCIALMENTE INAPROPIADA EN MAYORES DE 65 A\u00d1OS EN UN CENTRO DE SALUD DE \nATENCI\u00d3N PRIMARIA  \n \nLlauger MA, Rosas A, Burgos F, Torrente E, Tresserras R, Escarrabill J; en nombre del grupo de trabajo de espi rometr\u00eda \ndel Plan Director de las Enfermedades del Aparato Respiratorio (PDMAR). Accesibilidad y utilizaci\u00f3n de la espirometr\u00eda \nen los centros de atenci\u00f3n primaria de Catalu\u00f1a. Aten Primaria 2014;46:298 -306 [T,I]  \n24768654  R/C \nACCESIBILIDAD Y UTILIZACI\u00d3N DE LA ESPIROMETR\u00cdA EN LOS CENTROS DE ATENCI\u00d3N PRIMARIA DE \nCATALU\u00d1A  \n \nC\u00f3rdoba R. El desaf\u00edo de los cigarrillos electr\u00f3nicos. Aten Primaria 2014;46:307 -312 [R,II]  \n24704194  R/C \nEL DESAF\u00cdO DE LOS CIGARRILLOS ELECTR\u00d3NICOS  \n \nBRITISH MEDICAL JOURNAL  \n \nTammemagi  MC, Lam S. Screening for lung cancer using low dose computed tomography. BMJ 2014;348:g2253 [R,I]  \n24865600  R/C \nCRIBAJE DEL C\u00c1NCER DE PULM\u00d3N USANDO TOMOGRAF\u00cdA COMPUTADORIZADA DE DOSIS BAJA  \n \nLevy A. Interpreting raised serum prolactin results. BMJ 2014;348:g3207 [R,I]  \n24859901  \nINTERPRETACI\u00d3N DE LOS RESULTADOS DE PROLACTINA S\u00c9RICA ELEVADA  \n \nDormuth CR, Fil ion KB, Paterson JM, James MT, Teare GF, Raymond CB, et al; Canadian Network for Observational \nDrug Effect Studies (CNODES) Investigators. Higher potency statins and the risk of new diabetes: multicentre, \nobservational study of administrative databases. BMJ 2014;348:g3244 [T,II]  \n24874977  R/C \nESTATINAS DE GRAN POTENCIA Y RIESGO DE APARICI\u00d3N DE DIABETES: ESTUDIO OBSERVACIONAL \nMULTIC\u00c9NTRICO SOBRE BASES DE DATOS ADMINISTRATIVAS  \n \nSelak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on \nadherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in \nprimar y care. BMJ 2014;348:g3318 [EC,I]  \n24868083  R/C \nEFECTO DEL TRATAMIENTO CON DOSIS FIJAS COMBINADAS SOBRE EL CUMPLIMIENTO Y EL CONTROL DE \nFACTORES DE RIESGO EN PACIENTES CON RIESGO ALTO DE ENFERMEDAD CARDIOVASCULAR: ENSAYO \nCONTROLADO ALEATORIZADO EN ATENCI\u00d3N PRIMARIA  \n \nFord AC, Moayyedi P. Whom should we \"test and treat\" for Helicobacter pylori? BMJ 2014;348:g3320 [R,II]  \n24846521  \n\u00bfA QUI\u00c9N DEBER\u00cdAMOS \"ANALIZAR Y TRATAR\" DEL HELICOBACTER PYLORI?  \n \nMcCartney M. What should we die from? BMJ 2014;348:g3380 [AO,I]  \n24868097  \n\u00bfDE QU\u00c9 DEBER\u00cdAMOS MORIR?  \n \nCapewell  S. Sugar sweetened drinks should carry obesity warnings. BMJ 2014;348:g3428 [AO,I]  \n24870354   \n LAS BEBIDAS AZUCARADAS DEBER\u00cdAN LLEVAR ADVERTENCIAS CONTRA LA OBESIDAD  \n \nGumbinger C, Reuter B, Stock C,  Sauer T, Wieth\u00f6lter H, Bruder I, et al; AG Schlaganfall. Time to treatment with \nrecombinant tissue plasminogen activator and outcome of stroke in clinical practice: retrospective analysis of hospital \nquality assurance data with comparison with results fro m randomised clinical trials. BMJ 2014;348:g3429 [S,I]  \n24879819  R/C \nMOMENTO DEL TRATAMIENTO CON ACTIVADOR DEL PLASMIN\u00d3GENO TISULAR RECOMBINANTE Y \nRESULTADOS DEL ICTUS EN LA PR\u00c1CTICA CL\u00cdNICA: AN\u00c1LISIS RETROSPECTIVO DE DATOS DE LOS SEGUROS \nSOBRE CALIDAD HOSPITALARI A EN COMPARACI\u00d3N CON LOS RESULTADOS DE LOS ENSAYOS CL\u00cdNICOS \nALEATORIZADOS   \n \nHuffman MD. Fixed dose combinations of cardiovascular drugs. BMJ 2014;348:g3480 [AO,I]  \n24868084  \nDOSIS FIJAS COMBINADAS DE  F\u00c1RMACOS CARDIOVASCULARES  \n \nVaughan Jones S, Ambros -Rudolph C, Nelson -Piercy C. Skin disease in pregnancy. BMJ 2014;348:g3489 [R,I]  \n24895225  \nENFERMEDAD DE LA PIEL EN EL EMBARAZO  \n \nSeow  H, Brazil K, Sussman J, Pereira J, Marshall D, Austin PC, et al. Impact of community based, specialist palliative \ncare teams on hospitalisations and emergency department visits late in life and hospital deaths: a pooled analysis. BMJ \n2014;348:g3496 [S,I]  \n24906901  R/C \nIMPACTO DE LOS EQUIPOS ESPECIALIZADOS DE CUIDADOS PALIATIVOS EXTRAHOSPITALARIOS SOBRE LAS \nHOSPITALIZACIONES Y LAS VISITAS A URGENCIAS DE ENFERMOS TERMINAL ES Y MUERTES EN EL \nHOSPITAL: AN\u00c1LISIS COMBINADO  \n \nMaund E, Tendal B, Hr\u00f3bjartsson A, J\u00f8rgensen KJ, Lundh A, Schroll J, et al. Benefits and harms in clinical trials of \nduloxetine for treatment of major depressive disorder: comparison of clinical study report s, trial registries, and \npublications. BMJ 2014;348:g3510 [R,I]  \n24899650  R/C \nBENEFICIOS Y PERJUICIOS EN LOS ENSAYOS CL\u00cdNICOS DE DULOXETINA PARA EL TRATAMIENTO DEL \nTRAS TORNO DEPRESIBO MAYOR: COMPARACI\u00d3N DE INFORMES DE ESTUDIOS CL\u00cdNICOS, REGISTROS DE \nENSAYOS Y PUBLICACIONES  \n \nRueda -Clausen CF, Padwal RS. Pharmacotherapy for weight loss. BMJ 2014;348:g3526 [R,I]  \n24907124  \nFARMACOTERAPIA PARA PERDER PESO  \n \nMcDermott C. Patient outcomes at both ends of the stethoscope. BMJ 2014;348:g3575  [AO,I]  \nRESULTADOS EN EL PACIENTE A AMBOS LADOS DEL ESTETOSCOPIO  \n \nDoshi P, Zito J, dosReis S. Digging for data on harms in duloxetine  trials. BMJ 2014;348:g3578 [AO,I]  \n24904123  \nAHONDAR EN B\u00daSQUEDA DE DATOS SOBRE PERJUICIOS EN LOS ENSAYOS SOBRE DULOXETINA  \n \nLu CY, Zhang F, Lakoma MD, Madden JM, Rusinak D, Penfold  RB, et al. Changes in antidepressant use by young \npeople and suicidal behavior after FDA warnings and media coverage: quasi -experimental study. BMJ 2014;348:g3596 \n[QE,I]  \n24942789  R/C \nCAMBIOS EN EL USO DE LOS ANTIDEPRESIVOS POR PARTE DE LOS J\u00d3VENES Y COMPORTAMIENTO SUICIDA \nTRAS LAS ADVERTENCIAS DE LA FDA Y COBERTURA POR LOS MEDIOS DE COMUNICACI\u00d3N: ESTUDIO CUASI \nEXPERIMENTAL  \n \nYeo B, Turner NC, Jones A. An update on the m edical management of breast cancer. BMJ 2014;348:g3608 [R,I]  \n24912480  \nACTUALIZACI\u00d3N SOBRE EL TRATAMIENTO M\u00c9DICO DEL C\u00c1NCER DE MAMA  \n \nJ\u00f8rgensen T, Jacobsen RK, Toft U, Aadahl M, Gl\u00fcmer C, Pisinger C . Effect of screening and lifestyle counselling on \nincidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ 2014;348:g3617 [EC,II]  \n24912589  R/C \nEFECTO DEL CRIBAJE Y EL CONSEJO SOBRE H\u00c1BITOS EN LA INCIDENCIA DE ENFERMEDAD CARDIACA \nISQU\u00c9MICA EN LA POBLACI\u00d3N GENERAL: ENSAYO ALEATORIZADO INTER99  \n \nWolfe SM. A morphine -oxycodone combo pill: toward the \"holy grail\" for opioids  or a justifiably rejected drug? BMJ \n2014;348:g3620 [AO,I]  \n24912942  \nP\u00cdLDORA COMBINADA DE MORFINA -OXICODONA: \u00bfHACIA EL \"SANTO GRIAL\" DE LOS OPIOIDES O UN \nF\u00c1RMACO JUSTIFICADAMENTE RECHAZADO?   \n  \nJones C, Pollit V, Fitzmaurice D, Cowan C4; Guideline Development Group. The management of atrial fibrillation: \nsummary of updated NICE guidance. BMJ 2014;348:g3655 [M,III]  \n24948694  \nTRATAMIENTO DE LA FI BRILACI\u00d3N AURICULAR: RESUMEN DE LA GU\u00cdA NICE ACTUALIZADA  \n \nSch\u00f6ttker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot Ld, et al; Consortium on Health and Ageing: Network of \nCohorts in Europe and the United States (CHANCES). Vitamin D and mortality: meta -analysis of individual participant \ndata from a large consortium of cohort studies from Europe and the United States. BMJ 2014;348:g3656 [M,II]  \n24938302  R/C \nVITAMINA D Y MORTALIDAD: METAAN\u00c1LISIS DE DATOS DE PARTICIPANTES INDIVIDUALES DE UN GRAN \nCONSORCIO DE ESTUDIOS DE COHORTE DE EUROPA Y LOS ESTADOS UNIDOS  \n \nG\u00f8tzsche PC, J\u00f8rgensen KJ, Krogsb\u00f8ll LT. General health checks don't work. BMJ 2014;348:g3680 [AO,I]  \n24912801  \nLOS EX\u00c1MENES GENERALES DE SALUD NO FUNCIONAN  \n \nMurtagh F. Can palliative care teams relieve some of the pressure on acute services? BMJ 2014;348:g3693 [AO,I]  \n24906714  \n\u00bfPUEDEN LOS EQUIPOS DE CUIDADOS PALIATIVOS ALIVIAR ALGO DE LA PRESI\u00d3N SOBRE LOS SERVICIOS \nDE AGUDOS?  \n \nBoyd K, Murray SA. Why is talking about dying such a challenge? BMJ 2014;348:g3699 [AO, I] \n24906715  \n\u00bfPOR QU\u00c9 SUPONE ESE RETO EL HABLAR SOBRE LA MUERTE?  \n \nWeedon -Fekj\u00e6r H, Romundstad PR, Vatten LJ. Modern mammography screening and breast cancer mortality: \npopulation study. BMJ 2014 ;348:g3701 [S,II]  \n24951459   R/C \nEL MODERNO CRIBAJE MAMOGR\u00c1FICO Y LA MORTALIDAD POR C\u00c1NCER DE MAMA: ESTUDIO POBLACIONAL  \n \nGreenhalgh T, Howick J, Maskrey N; Evidence Bas ed Medicine Renaissance Group. Evidence based medicine: a \nmovement in crisis? BMJ 2014;348:g3725 [R,I]  \n24927763  \nMEDICINA BASADA EN LA EVIDENCIA: \u00bfUN MOVIMIENTO EN CRISIS?  \n \nGreenstone M, Hack M. Obstructive sleep apnoea. BMJ 2014;348:g3745 [R,I]  \n24939874  \nAPNEA OBSTRUCTIVA DEL SUE\u00d1O  \n \nChen Q, Sj\u00f6lander A, Runeson B, D'Onofrio BM, Lichtenstein P, Larsson H. Drug treatment for attention -\ndefic it/hyperactivity disorder and suicidal behaviour: register based study. BMJ 2014;348:g3769 [S,I]  \n24942388  R/C \nTRATAMIENTO FARMACOL\u00d3GICO DEL TRASTORNO DE HIPERACTIVIDAD/D\u00c9FICIT DE ATENCI\u00d3N Y \nCOMPOR TAMIENTO SUICIDA: ESTUDIO BASADO EN REGISTROS  \n \nElmore JG, Harris RP. The harms and benefits of modern screening mammography. BMJ 2014;348:g3824 [AO,I]  \n24938686  \nPERJUICIOS Y BENEFICIOS DEL CRIBAJE MAMOGR\u00c1FICO MODERNO  \n \nWindecker S, Stortecky S, Stefanini GG, daCosta BR, Rutjes AW, Di Nisio M et al. Revascularisation versus medical \ntreatment in patients with stable coronary artery disease: network meta -analysis. BMJ 2014;348:g3859 [M,II]  \n  R/C \nREVASCULARIZACI\u00d3N FRENTE A TRATAMIENTO M\u00c9DICO EN PACIENTES CON ENFERMEDAD ARTERIAL \nCORONARIA ESTABLE: METAAN\u00c1LISIS EN RED  \n \nRees J, Bultitud M, Challacombe B. The management of lower urinary tract symptoms in men. BMJ 2014 ;348:g3861 \n[R,II]  \n  R/C \nMANEJO DE LOS S\u00cdNTOMAS DE V\u00cdAS URINATIAS BAJAS EN HOMBRES  \n \nSridhar D, Frenk J, Gostin L, Moon S. Global rules for global health: why we need an independent, impartial WHO. BMJ \n2014;348:g3841 [AO,I]  \n24942299  \nREGLAS MUNDIALES PARA LA SALUD MUNDIAL: POR QU\u00c9 NECESITAMOS UNA OMS INDEPENDIENTE E \nIMPARCIAL  \n \nMcCartney M. How to undermine general practice. BMJ 2014;348:g4061 [AO,I]  \n24934620   \n C\u00d3MO MINAR LA MEDICINA GENERAL  \n \nZiada K, Moliterno DJ. Revascularisation for patients with stable coronary artery disease. BMJ 2014;348:g4099 [AO,I]  \nREVASCULARIZACI\u00d3N EN PACIENTES CON ENFER MEDAD ARTERIAL CORONARIA ESTABLE  \n \nJain A, Nundy S, Abbasi K. Corruption: medicine's dirty open secret. BMJ 2014;348:g4184 [AO,I]  \n24965786  \nCORRUPCI\u00d3N: EL SUCIO SECRETO ABIERTO DE LA MEDICINA  \n \nBRITISH JOURNAL OF PSYCHIATRY  \n \nOrrell M, Aguirre E, Spector A, Hoare Z, Woods RT, Streater A, et al. Maintenance cognitive stimulation therapy for \ndementia: single -blind, multicentre, pragmatic randomised controlled trial. Br J  Psychiatry 2014  [Epub ahead of print] \n[EC,I]  \n24676963  R/C \nTERAPIA DE MANTENIMIENTO DE ESTIMULACI\u00d3N COGNITIVA EN LA DEMENCIA: ENSAYO CONTROLADO \nALEATORIZADO PRAGM\u00c1TICO A DOBLE CIEGO MULTIC\u00c9NTRICO  \n \nMayou R. Is the DSM -5 chapter on somatic symptom disorder any better than DSM -IV somatoform disorder?  Br J \nPsychiatry 2014;204:418 -419 [AO,I]  \n\u00bfES EL CAP\u00cdTULO DEL DSM -5 SOBRE TRASTORNO DE S\u00cdNTOMAS SOM\u00c1TICOS MEJOR DE ALGUNA MANERA \nQUE EL TRASTORNO SOMATOFORME DEL DSM -IV? \n \nD'Amico F, Knapp M, Beecham J, Sandberg S, Taylor E, Sayal K. Use of services and associated costs for young adults \nwith childhood hyperactivity/conduct problems: 20 -year follow -up. Br J Psychiatry 20 14  [Epub ahead of print] [S,II]  \n24676966  R/C \nUSO DE SERVICIOS Y SUS COSTES ASOCIADOS POR PARTE DE J\u00d3VENES CON PROBLEMAS DE CONDUCTA \nE HIPERACTIVIDAD EN LA INFANCIA: 2 0 A\u00d1OS DE SEGUIMIENTO  \n \nQin P, Hawton K, Mortensen PB, Webb R. Combined effects of physical illness and comorbid psychiatric disorder on risk \nof suicide in a national population study. Br J Psychiatry 2014 [Epub ahead of print] [T,II]  \n24578445  R/C \nEFECTOS COMBINADOS DE ENFERMEDAD F\u00cdSICA Y TRASTORNO PSIQUI\u00c1TRICO COM\u00d3RBIDO SOBRE EL \nRIESGO DE SUICIDIO DENTRO DE UN ESTUDIO POBLACIONAL NACIONAL  \n \nVicens C, Bejarano F, Sempere E, Mateu C, Fiol F, Socias I, et al. Comparative efficacy of two interventions to \ndiscontinue long -term benzodiazepine use: cluster randomised controlled trial in primary care. Br J Psychiatry 2014 \n[Epub ahead of print] [EC,I]  \n24526745  R/C \nEFICACIA COMPARADA DE DOS INTERVENCIONES PARA DETENER EL USO DE BENZODIACEPINAS A LARGO \nPLAZO: ENSAYO CONTROLADO ALEATORIZADO POR GRUPOS EN ATENCI\u00d3N PRIMARIA  \n \nCANADIAN MEDICAL ASSOCIATION JOURNAL  \n \nGiddings G. Measles vaccination: a shot of common sense. CMAJ 2014;186:651 [AO,I]  \n24863920  \nVACUNA  DEL SARAMPI\u00d3N: UN DISPARO DE SENTIDO COM\u00daN  \n \nCaro -Bruce E, Flaxman G. Vulvar pruritus in a postmenopausal woman. CMAJ 2014;186:688 -689 [T,I]  \n24549132  \nPRURITO VULVAR EN MUJER POSTMENOP\u00c1USICA  \n \nCook VE, Chan ES. Anaphylaxis in the acute care setting. CMAJ 2014;186:694 [AO,I]  \n24591280  \nANAFILAXIA EN EL \u00c1MBITO DE LA ATENCI\u00d3N AGUDA  \n \nDixon A, Clarkin C, Barrowman N, Correll R, Osmond MH, Plint AC. Reduction of radial -head subluxation  in children by \ntriage nurses in the emergency department: a cluster -randomized controlled trial. CMAJ 2014;186:E317 -E323 [EC,I]  \n24664649  R/C \nREDUCCI\u00d3N DE LA SUBLUXACI\u00d3N DE LA CABEZA DEL RADIO EN NI\u00d1OS POR LAS ENFERMERAS DE TRIAJE \nEN EL SERVICIO DE URGENCIAS: ENSAYO CONTROLADO ALEATORIZADO POR GRUPOS  \n \nAfifi TO, MacMillan HL, Boyle M, Taillieu T, Cheung K, Sareen J. Child abuse and mental disorders in Canada. CMAJ \n2014;186:E324 -E332 [T,I]  \n24756625  R/C \nMALTRATO INFANTIL Y TRASTORNOS MENTALES EN CANAD\u00c1  \n \nKennedy SA, Baerlocher MO. New and experimental approaches to back pain. CMAJ 2014;186:E340 [AO,I]  \n24516088   \n ABORDAJES NUEVOS Y EXPERIMENTALES DEL DOLOR DE ESPALDA  \n \nCIRCULATION  \n \nSmilowitz NR, Donnino R, Schwartzbard  A. Glucagon -like Peptide -1 receptor agonists for diabetes mellitus: a role in \ncardiovascular disease. Circulation 2014;129:2305 -2312 [R,I]  \n24891623  \nAGONISTAS DEL RECEPTOR GLP -1 PARA LA DIABETES M ELLITUS: PAPEL EN LA ENFERMEDAD \nCARDIOVASCULAR  \n \nWong CX, Lau DH, Sanders P. Atrial fibrillation epidemic and hospitalizations: how to turn the rising tide? Circulation \n2014;129:2361 -2363 [AO,I]  \n24842944  \nEPIDEMIA DE FIBRILACI\u00d3N AURICULAR Y HOSPITALIZACIONES: \u00bfC\u00d3MO PARAR LA SUBIDA DE LA MAREA?  \n \nPatel NJ, Deshmukh A, Pant S, Singh V, Patel N, Arora S, et al. Contemporary trends of hospitalization for atrial \nfibrillation in the United States, 2000 th rough 2010: implications for healthcare planning. Circulation 2014;129:2371 -2379 \n[T,II] \n24842943  R/C \nTENDENCIAS CONTEMPOR\u00c1NEAS DE HOSPITALIZACI\u00d3N POR FIBRILACI\u00d3N AURIC ULAR EN LOS EE UU, DE \n2000 A 2010: IMPLICACIONES PARA LA PLANIFICACI\u00d3N DE LA ATENCI\u00d3N SANITARIA  \n \nZaman S, Kovoor P. Sudden cardiac death early after myocardial infarction: pathogenesis, risk stratification, and primary \nprevention. Circulation 2014;129:2426 -2435 [R,I]  \n24914016  \nMUERTE S\u00daBITA CARDIACA PRECOZ TRAS INFARTO DE MIOCARDIO: PATOG\u00c9NESIS, ESTRATIFICACI\u00d3N DEL \nRIESGO Y PREVENCI\u00d3N PRIMARIA  \n \nGoldfine AB, Phua EJ, Abrahamson MJ. Glycemic managemen t in patients with coronary artery disease and prediabetes \nor type 2 diabetes mellitus. Circulation 2014;129:2567 -2573 [R,I]  \n24934464  \nMANEJO GLUC\u00c9MICO EN PACIENTES CON ENFERMEDAD ARTERIAL CORONARI A Y PREDIABETES O \nDIABETES MELLITUS TIPO 2  \n \nMenon V, Lincoff AM. Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus. Circulation \n2014;129:2705 -2713 [R,II]  \n24958 753 \nEVALUACI\u00d3N DE LA SEGURIDAD CARDIOVASCULAR EN EL DESARROLLO DE NUEVOS F\u00c1RMACOS PARA LA \nDIABETES MELLITUS  \n \nAntman EM, Appel LJ, Balentine  D, Johnson RK, Steffen LM, Miller EA, et al. Stakeholder discussion to reduce \npopulation -wide sodium intake and decrease sodium in the food supply: a conference report from the american heart \nassociation sodium conference 2013 planning group. Circulation 2014;129:e660 -e679 [T,I]  \n24799511  R/C \n \nDIABETES CARE  \n \nHome P, Riddle M, Cefalu WT, Bailey CJ, Bretzel  RG, Del Prato S, et al. Insulin therapy in people with type 2 diabetes: \nopportunities and challenges? Diabetes Care 2014;37:1499 -1508 [R,I]  \n24855154  R/C \nTRATAMIENTO C ON INSULINA EN PERSONAS CON DIABETES TIPO 2: \u00bfOPORTUNIDADES Y RETOS?  \n \nFeig DS, Hwee J, Shah BR, Booth GL, Bierman AS, Lipscombe LL. Trends in incidence of diabetes in pregnancy and \nserious perinatal outcomes: a large, population -based study in Ontario, Canada, 1996 -2010. Diabetes Care \n2014;37:1590 -1596 [S,I]  \n24705609  R/C \nTENDENCIAS EN LA INCIDENCIA DE DIABETES EN EL EMBARAZO Y RESULTADOS PERINATALES GRAVES: \nESTUDIO POBLACIONAL EXTENSO EN ONTARIO, CANAD\u00c1, DE 1996 A 2010  \n \nLaxy M, Mielck A, Hunger M, Schunk M, Meisinger C, R\u00fcckert IM, et al. The association between patient -reported self -\nmanagement behavior, intermediate clinical outcomes, and mortality in patient s with type 2 diabetes: results from the \nKORA -A study. Diabetes Care 2014;37:1604 -1612 [S,II]  \n24667462  R/C \nASOCIACI\u00d3N ENTRE AUTOMANEJO INFORMADO POR EL PACIENTE, RESULTADOS CL\u00cdNICOS INTERMEDIOS Y \nMORTALIDAD EN PACIENTES CON DIABETES TIPO 2: RESULTADOS DEL ESTUDIO KORA -A \n \nH\u00e4ring HU, Merker L, Seewaldt -Becker E, Weimer M, Meinicke T, Broedl UC, et al; EMPA -REG MET Trial Investigators. \nEmpagliflozin as add -on to metfo rmin in patients with type 2 diabetes: a 24 -week, randomized, double -blind, placebo -\ncontrolled trial. Diabetes Care 2014;37:1650 -1659. doi [EC,II]   \n 24722494  R/C \nEMPAGLIFLOOZINA A\u00d1ADIDA A LA METFORMINA EN PACIENTES CON DIABETES TIPO 2: ENSAYO DE 24 \nSEMANAS ALEATORIZADO DOBLE CIEGO CONTROLADO CON PLACEBO  \n \nWaaijman R, de Haart M, Arts ML, Wever D, Verlouw AJ, Nollet F, et al. Risk factors for plantar foot ulcer recur rence in \nneuropathic diabetic patients. Diabetes Care 2014;37:1697 -1705 [S,I]  \n24705610  R/C \nFACTORES DE RIESGO PARA LA RECURRENCIA DE LA \u00daLCERA PLANTAR DEL PIE EN PACIE NTES CON \nNEUROPAT\u00cdA DIAB\u00c9TICA  \n \nMargolis KL, O'Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined \ncardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care \n2014;37:1721 -1728  [EC,II]  \n24595629  R/C \nRESULTADOS DE LAS ESTRATEGIAS COMBINADAS DE MANEJO DE LOS FACTORES DE RIESGO \nCARDIOVASCULAR EN LA DIABETES TIPO 2: ENSAYO ALEATORIZADO ACCORD  \n \nPal K, Eastwood SV, Michie S, Farmer A, Barnard ML, Peacock R, et al. Computer -based interventions to improve self -\nmanagement in adults with type 2 diabetes: a systematic review and meta -analysis. Diabetes Care 2014;37:1759 -1766 \n[M,I] \n24855158  R/C \nINTERVENCIONES MEDIANTE ORDENADOR PARA MEJORAR EL AUTOMANEJO EN ADULTOS CON DIABETES \nTIPO 2: REVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS  \n \nGrunberger G. Insulin analogs -are they worth it? Yes! Diabetes Care 2014;37:1767 -1770 [AO,I]  \n24855159  R/C \n\u00bfMERECEN LA PENA LOS AN\u00c1LOGOS DE LA INSULINA? \u00a1S\u00cd! \n \nDavidson MB. Insulin analogs -is there a compelling case to use them? No! Diabetes Care 2014;37:1771 -1774 [AO,I]  \n24855160  R/C \n\u00bfHAY UNA RAZ\u00d3N CONVINCENTE PARA UTILIZAR L OS AN\u00c1LOGOS DE LA INSULINA? \u00a1NO!  \n \nDRUGS  \n \nAlsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs 2014;74:839 -\n854 [R,II]  \n24846578   R/C \nMONITORIZACI\u00d3N TERAP\u00c9UTICA DE LOS F\u00c1RMACOS EN EL TRATAMIENTO DE LA TUBERCULOSIS: \nACTUALIZACI\u00d3N  \n \nBschor T. Lithium in the treatment of major depressive disorder. Drugs 2014;74:855 -862 [R,I]  \n24825489   R/C \nLITIO EN EL TRATAMIENTO DEL TRASTORNO DEPRESIVO MAYOR  \n \nHilgenfeld R, Seipke G, Berchtold H, Owens DR. The evolution of insulin glargine and its continuing contribution to \ndiabetes care. Drugs 2014;74:911 -927 [R,II]  \n24866023   R/C \nEVOLUCI\u00d3N DE LA INSULINA GLARGINA Y SU CONTINUA CONTRIBUCI\u00d3N A LA ATENCI\u00d3N A LA DIABETES  \n \nBichoupan K, Dieterich DT. Hepatitis C in HIV -infected patients: impact of direct -acting antivirals. Drugs 2014;74:951 -961 \n[R,I] \n24866024   R/C \nHEPATITIS C EN PACIENTES INFECTADOS CON VIH: IMPACTO DE LOS ANTIV\u00cdRICOS DIRECTOS  \n \nChrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some \ninsights on its role in heart failure and peripheral artery disease. Drugs 2014;74 :971-980 [R,I]  \n24902800   R/C \nDEFINIR EL PAPEL DE LA TRIMETAZIDINA EN EL TRATAMIENTO DE LOS TRASTORNOS CARDIOVASCULARES: \nALGUNAS REFLEXIONES SOBRE SU PAPEL EN LA INSUFI CIENCIA CARDIACA Y LA ENFERMEDAD ARTERIAL \nPERIF\u00c9RICA  \n \nEUROPEAN HEART JOU RNAL  \n \nArnold SV, Spertus JA, Nallamothu BK. The hostile heart: anger as a trigger for acute cardiovascular events. Eur Heart J \n2014;35:1359 -1360 [AO,I]  \n24591549  \nEL CORAZ\u00d3N HOSTIL: LA IRA COMO DESENCADENANTE DE ACONTECIMIENTOS CARDIOVASCULARES \nAGUDOS  \n  \n Della Rocca DG, Pepine CJ. Some thoughts on the continuing dilemma of angina pectoris. Eur Heart  J 2014;35:1361 -\n1364 [AO,I]  \n23045268  \nALGUNOS PENSAMIENTOS SOBRE EL CONTINUO DILEMA DE LA ANGINA DE PECHO  \n \nHare DL, Toukhsati SR, Johansson P, Jaarsma  T. Depression and cardiovascular disease: a clinical review. Eur Heart J \n2014;35:1365 -1372 [R,I]  \n24282187  R/C \nDEPRESI\u00d3N Y ENFERMEDAD CARDIOVASCULAR: REVISI\u00d3N CL\u00cdNICA  \n \nGustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of acute \nmyocardial infarction: the HUNT 2 study. Eur Heart J 2014;35:1394 -1403 [S,II]  \n2405707 7 R/C \nS\u00cdNTO MAS DE ANSIEDAD Y DEPRESI\u00d3N Y RIESGO DE INFARTO AGUDO DE MIOCARDIO: ESTUDIO HUNT 2  \n \nMostofsky E, Penner EA, Mittleman MA. Outbursts of anger as a trigger of acute cardiovascular events: a systematic \nreview and meta -analysis\u2020. Eur Heart J 2014;35:1404 -1410 [M,II]  \n24591550  R/C \nESTALLIDOS DE IRA COMO DESENCADENANTE DE ACONTECIMIENOTOS AGUDOS CARDIOVASCULARES: \nREVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS  \n \nConnolly SJ. Real -world experience with atrial fibrillation ablation: cause for concern. Eur Heart J 2014;35:1430 -1432 \n[AO,I]  \n24468887  \nEXPERIENCIA EN EL MUNDO REAL CON LA ABLACI\u00d3N EN  LA FIBRILACI\u00d3N AURICULAR: CAUSA  DE \nPREOCUPACI\u00d3N  \n \nWasmer K, Breithardt G, Eckardt L. The young patient with asymptomatic atrial fibrillation: what is the evidence to leave \nthe arrhythmia untreated? Eur Heart J 2014;35:1439 -1447 [R,I]  \n24639425  R/C \nEL PACIENTE JOVEN CON FIBRILACI\u00d3N AURICULAR ASINTOM\u00c1TICA: \u00bfCU\u00c1L ES LA EVIDENCIA PARA DEJAR \nLA ARRITMIA SIN TRATAR?  \n \nNattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL, et al. Early management of atrial fibrillation to \nprevent cardiovascular complications. Eur Heart J 2014;35:1448 -1456 [R,II]  \n24536084  R/C \nMANEJO PRECOZ DE  LA FIBRILACI\u00d3N AURICULAR PARA PREVENIR LAS COMPLICACIONES \nCARDIOVASCULARES  \n \nFAMILY MEDICINE  \n \nWillis DR, Bennett I, Jones BG, Renshaw SE, Holley M, Dankoski ME.  Practice -based learning and improvement in \nfamily medicine student clerkships: a CERA study. Fam Med 2014;46:423 -428 [T,II]  \n24911296   R/C \nAPRENDIZAJE BASADO EN LA PR\u00c1 CTICA Y MEJOR\u00cdA DE LAS ROTACIONES DE LOS ESTUDIANTES EN \nMEDICINA DE FAMILIA: ESTUDIO CERA  \n \nTaylor JS, George PF, MacNamara MM, Zink D, Patel NK, Gainor J, et al. A new clinical skills clerkship for medical \nstudents. Fam Med 2014;46:433 -439 [S,I]  \n24911298   R/C \nNUEVA ROTACI\u00d3N SOBRE  HABILIDADES CL\u00cdNICAS PARA ESTUDIANTES DE MEDICINA  \n \nCollins L, Sato R, LaNoue M, Michaluk L, Verma  M. Impact of a patient -centered medical home clerkship curriculum. \nFam Med 2014;46:440 -446 [C,I]  \n24911299   R/C \nIMPACTO DE UN CURR\u00cdCULO DE ROTACI\u00d3N CENTRADA EN EL PACI ENTE  \n \nRingoir L, Pedersen SS, Widdershoven JW, Pouwer F, Keyzer JM, Romeijnders AC, et al. Beta -blockers and depression \nin elderly hypertension patients in primary care. Fam Med 2014;46:447 -453 [T,I]  \n24911300   R/C \nBETA -BLOQUEANTES Y DEPRESI\u00d3N EN PACIENTES ANCIANOS CON HIPERTENSI\u00d3N EN ATENCI\u00d3N PRIMARIA  \n \nFAMILY PRACTICE  \n \nSolberg LI. Patient outcomes measures -the next promising answer? Fam Pract 2014;31:245 -246 [AO,I]  \n24835234  \nMEDIDAS DE RESULTADOS EN EL PACIENTE \u00bfLA PR\u00d3XIMA RESPUESTA PROMETEDORA?  \n  \n Unverzagt S, Oem ler M, Braun K, Klement A. Strategies for guideline implementation in primary care focusing on \npatients with cardiovascular disease: a systematic review. Fam Pract 2014;31:247 -266 [M,II]  \n24367069  R/C \nESTRATEGIAS PARA LA PUESTA EN MARCHA DE GU\u00cdAS EN ATENCI\u00d3N PRIMARIA CENTRADAS EN LOS \nPACIENTES CON ENFERMEDAD CARDIOVASCULAR: REVISI\u00d3N SISTEM\u00c1TICA  \n \nvan der Zwaard BC, Poppe E, Vanwanseele B, van der Horst HE, Elders PJ. Deve lopment and evaluation of a leaflet \ncontaining shoe advice: a randomized controlled trial. Fam Pract 2014;31:267 -272 [EC,I]  \n24435069  R/C \nDESARROLLO Y EVALUACI\u00d3N DE UN FOLLETO CON CONSEJOS PARA LOS PIES: ENSAYO CONTROLADO \nALEATORIZADO  \n \nBoffin N, Moreels S, Vanthomme K, Van Casteren V. Falls among older general practice patients: a 2 -year nationwide \nsurveillance study. Fam Pract 2014;31:281 -289 [T,II]  \n24532609  R/C \nCA\u00cdDAS EN PACIENTES ANCIANOS EN MEDICINA GENERAL: ESTUDIO DE VIGILANCIA DURANTE 2 A\u00d1OS  \n \nFitzmaurice DA, McCahon D, Baker J, Murray ET, Jowett S, Sandhar H, et al.  Is screening for AF worthwhile? Stroke risk \nin a screened population from the SAFE study. Fam Pract 2014;31:298 -302 [S,I]  \n24728774  R/C \n\u00bfMERECE LA PENA EL CRIBADO DE L A FIBRILACI\u00d3N AURICULAR ? RIESGO DE ICTUS EN UNA POBLACI\u00d3N \nCRIBADA DEL ESTUDIO SAFE  \n \nG\u00f6rig T, Mayer M, Bock C, Diehl K, Hilger J, Herr RM, et al. Dietary counselling for cardiovascular disease prevention in \nprimary care settings: results from a German physi cian survey. Fam Pract 2014;31:325 -332 [T,I]  \n24639564  R/C \nCONSEJO DIET\u00c9TICO PARA LA PREVENCI\u00d3N DE LA ENFERMEDAD CARDIOVASCULAR EN EL \u00c1MBITO DE LA \nATENCI\u00d3N PRIMARIA: RESULTADOS DE UNA ENCUESTA EN M\u00c9DICOS ALEMANES  \n \nStijnen MM, Van Hoof MS, Wijnands -Hoekstra IY, Guldemond -Hecker Y, Duimel -Peeters IG, Vrijhoef HJ, et al. Detected \nhealth and well -being problems following comprehensive geriatric assessment during a home vis it among community -\ndwelling older people: who benefits most? Fam Pract 2014;31:333 -340 [T,I]  \n24736294  R/C \nPROBLEMAS DE SALUD Y BIENESTAR DETECTADOS SIGUIENDO UNA VALOR ACI\u00d3N GERI\u00c1TRICA INTEGRAL \nDURANTE LA VISITA DOMICILIARIA EN PERSONAS MAYORES QUE VIVEN EN LA COMUNIDAD: \u00bfQUI\u00c9N SE \nBENEFICIA M\u00c1S?  \n \nFurler JS, Blackberry ID, Walker C, Manski -Nankervis JA, Anderson J, O'Neal D, et al. Stepping up: a nurse -led model of \ncare f or insulin initiation for people with type 2 diabetes. Fam Pract 2014;31:349 -356 [C,I]  \n24473676  R/C \nUN PASO ADELANTE: MODELO DE ATENCI\u00d3N DIRIGIDO POR ENFERMERAS PARA LA INICIACI\u00d3N EN LA \nINSULINA DE PERSONAS CON DIABETES TIPO 2  \n \nBishop FL, Howick J, Heneghan C, Stevens S, Hobbs FD, Lewith G. Placebo use in the UK: a qualitative study exploring \nGPs' views on placebo effects in clinical practice. Fam Pract 2014;31:357 -363 [C,I] \n24736295  R/C \nUSO DE PLACEBO EN RU: ESTUDIO CUALITATIVO PARA EXPLORAR LOS PUNTOS DE VISTA DE LOS M\u00c9DICOS \nGENERALES SOBRE LOS EFECTOS PLACEBO EN LA PR\u00c1CTICA CL\u00cdNI CA \n \nJenkinson CE, Winder RE, Sugg HV, Roberts MJ, Ridgway N, Kuyken W, et al. Why do GPs exclude patients from \nparticipating in research? An exploration of adherence to and divergence from trial criteria. Fam Pract 2014;31:364 -370 \n[C,I] \n24621557  R/C \n\u00bfPOR QU\u00c9 EXCLUYEN LOS M\u00c9DICOS GENERALES A PACIENTES DE LA PARTICIPACI\u00d3N EN LA \nINVESTIGACI\u00d3N? EXPLORACI\u00d3N DEL SEGUIMIENTO Y DE LA DISCREPANCIA DE LOS CRITERIOS DE LOS \nENSAYOS  \n \nJOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  \n \nMortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, et al. Association of azithromycin with mortality \nand cardiovascular events among older patients hospitalized with pneum onia. JAMA 2014;311:2199 -2208 [S,I]  \n24893087   R/C \nASOCI ACI\u00d3N DE LA AZITROMICINA CON MO RTALIDAD Y ACONTECIMIENTOS CARDIOVASCULARES ENTRE \nPACIENTES MAYORES HOSPITALI ZADOS CON NEUMON\u00cdA  \n \nAl-Khatib SM, Hellkamp AS, Fonarow GC, Mark DB, Curtis LH, Hernandez AF, et al. Association between prophylactic \nimplantable cardioverter -defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35% . \nJAMA 2014;311:2209 -2215 [S,I]  \n24893088   R/C  \n ASOCIACI\u00d3N ENTRE CARDIOVERSORES -DESFIBRILADORES IMPLANTABLES PR EVENTIVOS  Y \nSUPERVIVENCIA EN PACIENTES CON FRACCI\u00d3N DE EYE CCI\u00d3N VENTRICULAR IZQUIERDA ENTRE 30 Y 35 %  \n \nSalt restriction. JAMA 2014;311:2229 [AO,I]  \n24893092   \nRESTRICCI\u00d3N DE SAL  \n \nSeaquist ER. Addressing the burden of diabetes. JAMA 2014;311:2267 -2268 [AO,I]  \n24915253   \nABORDAR LA CARGA DE DIABETES  \n \nJampol LM, Bressler NM, Glassman AR. Revolution to a new standard treatment of diabetic macular edema. JAMA \n2014;311:2269 -2270 [AO,I]  \n24915254   \nREVOLUCI\u00d3N HACIA UN NUEVO EST\u00c1NDAR DE TRATAMIENTO DEL EDEMA MACULAR DIAB\u00c9TICO  \n \nSacks DB, John WG. Interpretation of hemoglobin A1c values. JAMA 2014;311:2271 -2272 [AO,I]  \n24915255   \nINTERPRETACI\u00d3N DE LOS VALORES DE HEMOGLOBINA A1C  \n \nRoumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, et al. Association between intensification of metformin  \ntreatment with insulin vs sulfonylureas and cardiovascular events and all -cause mortality among patients with diabetes. \nJAMA 2014;311:2288 -2296 [S,II]  \n24915260   R/C \nASOCIACI\u00d3N ENTRE INTENSIFICACI\u00d3N DEL TRATAMIENTO DE METFORMINA CON INSULINA FRENTE A \nSULFONILUREAS Y ACONTECIMIENTOS CARDIOVASCULARES Y MORTALIDAD POR CUALQUIER CAUSA \nENTRE PACIENTES CON DIABETES  \n \nWallia A, Molitch ME. Insulin therapy for type 2 diabetes m ellitus. JAMA 2014;311:2315 -2325 [M,II]  \n24915263   R/C \nTERAPIA CON INSULINA EN LA DIABETES MELLITUS TIPO 2  \n \nAndrews MA, O'Malley PG. Diabetes overtreatment in elderly i ndividuals: risky business in need of better management. \nJAMA 2014;311:2326 -2327 [AO,I]  \n24915264   \nSOBRETRATAMIENTO DE LA DIABETES EN LAS PERSONAS MAYORES: ASUNTO ARRIESGADO QUE \nREQUIERE UN MANEJO MEJOR  \n \nBeckman JA. Thrombolytic therapy for pulmonary embolism. JAMA 2014;311:2385 -2386 [AO,I]  \n24938561   \nTERAPIA TROMBOL\u00cdTICA EN EL EMBOLISMO PULMONAR  \n \nCoresh J, Turin TC, Matsushita K, Sang Y, Ba llew SH, Appel LJ, et al; for the CKD Prognosis Consortium. Decline in \nestimated glomerular filtration rate and subsequent risk of end -stage renal disease and mortality. JAMA 2014 [Epub \nahead of print] [M,II]  \n24892770   R/C \nCA\u00cdDA EN LA TASA DE FLUJO GLOMERULAR ESTIMADA Y RIESGO POSTERIOR DE ENFERMEDAD RENAL \nTERMINAL Y MORTALIDAD  \n \nPahor M, Guralnik JM, Ambrosius  WT, Blair S, Bonds DE, Church TS, et al; LIFE study investigators. Effect of structured \nphysical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA \n2014;311:2387 -2396 [EC,II]  \n24866862   R/C \nEFECTO DE LA ACTIVIDAD F\u00cdSICA ESTRUCTURADA SOBRE LA PREVENCI\u00d3N DE DISCAPACIDAD IMPORTANTE \nDE LA MOVILIDAD EN ANCIANOS: ENSAYO CL\u00cdNICO ALEATORIZADO ESTUDIO LIFE  \n \nCooney G, Dwan K, Mead G. Exercise for depression. JAMA 2014;311:2432 -2433 [AO,II]  \n24938566   R/C \nEJERCICIO PARA LA DEPRESI\u00d3N  \n \nLudwig DS, Friedman MI. Increasing adiposity: consequence or cause of overeating? JAMA 2014;311:2167 -2168 [AO,I]  \n24839118   \nAUMENTO DE LA ADIPOSIDAD: \u00bfCONSECUENCIA O CAUSA DEL EXCESO DE COMIDA?  \n \nHerath SC, Poole P. Prophylactic antibiotic therapy in chronic obstructive pulmonary disease. JAMA 2014;311:2225 -\n2226 [AO,II]  \n24893090   R/C \nTERAPIA DE PROFILAXIS ANTIBI\u00d3TICA EN LA EPOC  \n  \n Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA 2014;311:2216 -2224 [R,II]  \n24893089   R/C \nHIPERTENSI\u00d3N RESIST ENTE: REVISI\u00d3N DEL DIAGN\u00d3STICO Y TRATAMIENTO  \n \nO'Meara S, Richardson R, Lipsky BA. Topical and systemic antimicrobial therapy for venous leg ulcers . JAMA \n2014;311:2534 -2535 [AO,I]  \n  R/C \nTERAPIA ANTIMICROBIANA T\u00d3PICA Y SIST\u00c9MICA PA RA LAS \u00daLCERAS VENOSAS DE LAS PIERNAS  \n \nPisano ED, Yaffe MJ. Breast cancer screening: should tomosynthesis replace digital mammography? JAMA \n2014;311:2488 -2489 [AO,I]  \n  R/C \nCRIBAJE DEL C\u00c1NCER DE MAMA: \u00bfDEBER\u00cdA LA TOM OS\u00cdNTESIS REEMPLAZAR A LA MAMOGRAF\u00cdA DIGITAL?  \n \nFriedewald SM, Rafferty EA, Rose SL, Durand MA, Plecha DM, Greenberg JS, et al. Breast cancer screening using \ntomosynthesis in combination with digital mammography. JAMA 2014;311:2499 -2507 [T,II]  \n  R/C \nCRIBAJE DEL C\u00c1NCER DE MAMA USANDO TOMOS\u00cdNTESIS EN COMBINACI\u00d3N CON MAMOGRAF\u00cdA DIGITAL  \n \nJAMA INTERNAL MEDICINE  \n \nFoy AJ, Ting JG. The harms of an unnecessary preoperative echocardiogram: a teachable moment. JAMA Intern Med \n2014;174:853 -854 [AO,I]  \n24687089   \nLOS PERJUICIOS DE UN ECOCARDIOGRAMA PERIOPERATORIO INNECESARIO: MOMENTO DE APRENDIZAJE  \n \nTannenbaum C, Martin P, Tamblyn  R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions \namong older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med \n2014;174:890 -898 [EC,II]  \n24733354   R/C \nREDUCCI\u00d3N DE PRESCRIPCIONES INADECUADAS DE BENZODIACEPINAS ENTRE ANCIANOS A TRAV\u00c9S DE LA \nEDUCACI\u00d3N DIRECTA DEL PACIENTE: ENSAYO ALEATORIZADO AGRUPADO EMPOW ER \n \nHuffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, et al. Collaborative care for depression \nand anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology \n(MOSAIC) randomized clinica l trial. JAMA Intern Med 2014;174:927 -936 [EC,I]  \n24733277   R/C \nATENCI\u00d3N COORDINADA A LA DEPRESI\u00d3N Y LOS TRASTORNOS D E ANSIEDAD EN PACIENTES CON \nACO NTECIMIENTOS CARDIACOS RECIENTES: ENSAYO CL \u00cdNICO ALEATO RIZADO MOSAIC  \n \nTosteson AN, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, et al. Consequences of false -positive \nscreening mammograms. JAMA Intern Med 2014;174:954 -961 [S,I]  \n24756610   R/C \nCONSECUENCIAS DE LOS FALSOS POSITIVOS EN LAS MAMOGRAF\u00cdAS DE CRIBAJE  \n \nLi WQ, Qureshi AA, Robinson KC, Han J. Sildenafil use and increased risk of incident melanoma in US men: a \nprospective  cohort study. JAMA Intern Med 2014;174:964 -970 [S,I]  \n24710960   R/C \nUSO DE SILDENAFILO Y AUMENTO DEL RIESGO DE MELANOMA EN HOMBRES ESTADOUNIDENSES: ESTUDIO \nDE COHORTE PROSPECTIVO  \n \nJAMA PSYCHIATRY  \n \nCorrell CU, Carbon M. Efficacy of pharmacologic and psychotherapeutic interventions in psychiatry: to talk or to \nprescribe: is that the question? JAMA Psychiatry 2014;71:624 -626 [AO,I]  \n24789579   \nEFICACIA DE LAS INTERVENCIONES FARMACOL\u00d3GICAS Y PSICOTERAP\u00c9UTICAS EN PSIQUIATR\u00cdA: HABLAR O \nPRESCRIBIR \u00bfES ESE EL DILEMA?  \n \nHuhn M, Tardy M, Spineli LM, Kissling W, F\u00f6rstl H, Pitschel -Walz  G, et al. Efficacy of pharmacotherapy and \npsychotherapy for adult psychiatric disorders: a systematic overview of meta -analyses. JAMA Psychiatry 2014;71:706 -\n715 [M,II]  \n24789675   R/C \nEFICACIA DE LA FARMACOTERAPIA Y LA PSICOTERAPIA EN LOS TRASTORNOS PSIQUI\u00c1TRICOS DEL \nADULTO: RESUMEN SISTEM\u00c1TICO DE METAAN\u00c1LISIS  \n \nMEDICINA CLINICA  \n  \n Gonz\u00e1lez -Molero I, Rojo G, Morcillo S, P\u00e9rez -Valero V, Rubio -Mart\u00edn E, Gutierrez -Repiso C, Soriguer F. Relaci\u00f3n entre \nd\u00e9ficit de vitamina D y s\u00edndrome metab\u00f3lico. Med Clin (Barc) 2014;142:473 -477 [S,II]  \n24216018  R/C \nRELACI\u00d3N ENTRE D\u00c9FICIT DE VITAMINA D Y S\u00cdNDROME METAB\u00d3LICO  \n \nGonz\u00e1lez -Clemente JM, Font B, Lahoz R, Llaurad\u00f3 G, Gamb\u00fas G; Grupo de investigadores del Estudio INERCIA. \nInercia cl\u00ednica en pacientes con diabetes mellitus tipo 2 no insuliniz ados en tratamiento con hipoglucemiantes orales. \nEstudio INERCIA. Med Clin (Barc) 2014;142:478 -484 [T,II]  \n23622897  R/C \nINERCIA CL\u00cdNICA EN PACIENTES CON DIABETES MELLIT US TIPO 2 NO INSULINIZADOS EN TRATAMIENTO \nCON HIPOGLUCEMIANTES ORALES. ESTUDIO INERCIA  \n \nGomis R, Artola S, Conthe P, Vidal J, Casamor R, Font B; investigadores del Grupo de Estudio OBEDIA. Prevalencia de \ndiabetes mellitus tipo 2 en pacientes ambulatorios c on sobrepeso u obesidad en Espa\u00f1a. Estudio OBEDIA. Med Clin \n(Barc) 2014;142:485 -492 [T,II]  \n23683969  R/C \nPREVALENCIA DE DIABETES MELLITUS TIPO 2 EN PACIENTES AMBULATORI OS CON SOBREPESO U \nOBESIDAD EN ESPA\u00d1A. ESTUDIO OBEDIA  \n \nGonz\u00e1lez -Parra E, Egido J. Vitamina D, s\u00edndrome metab\u00f3lico y diabetes mellitus. Med Clin (Barc) 2014;142:493 -496 \n[AO,I]  \n24629694  \nVITAMINA D, S\u00cdNDROME METAB\u00d3LICO Y DIABETES MELLITUS  \n \nLim\u00f3n -Ram\u00edrez R, Gea -Vel\u00e1zquez de Castro MT, Aranaz -Andr\u00e9s JM. Dise\u00f1o de una estrategia multimodal incluyendo \nmarketing sanitario para la mejora del cumplimiento de la higiene de manos. Med Clin (Barc) 2014;142:505 -511 [R,I]  \n24387954  \nDISE\u00d1O DE UNA ESTRATEGIA MULTIMODAL INCLUYENDO MARKETING SANITARIO PARA LA MEJORA DEL \nCUMPLIMIENTO DE LA HIGIENE DE MANOS  \n \nMorillas RM, Sala M, Planas R. Profilaxis de la encefa lopat\u00eda hep\u00e1tica. Med Clin (Barc) 2014;142:512 -514 [AO,I]  \n24480288  R/C \nPROFILAXIS DE LA ENCEFALOPAT\u00cdA HEP\u00c1TICA  \n \nFaro M, S\u00e1ez -Franc\u00e0s N, Castro -Marrero J, Aliste L, Col lado A, Alegre J. Impacto de la fibromialgia en el s\u00edndrome de \nfatiga cr\u00f3nica. Med Clin (Barc) 2014;142:519 -525 [T,I]  \n24387955  R/C \nIMPACTO DE LA FIBROMIALGIA EN EL S\u00cdNDROME DE FATIGA CR\u00d3NICA  \n \nMart\u00edn -Ramiro JJ, Alvarez -Mart\u00edn E, Gil -Prieto R. Mortalidad atribuible al exceso de peso en Espa\u00f1a. Med Clin (Barc) \n2014;142:526 -530 [T,II]  \n24183117  R/C \nMORTALIDAD ATRIBUIBLE AL EXCESO DE PESO EN ESPA\u00d1A  \n \nRico-Villademoros F, Calandre EP. Fibromialgia: \u00bfcomorbilidad marcadora de vulnerabilidad? Med Clin (Barc) \n2014;142:538 -539 [AO,I]  \n24315748  \nFIBROMIALGIA: \u00bfCOMORBILIDAD MARCADORA DE VULNERABILIDAD?  \n \nHern\u00e1ndez FJ, Ruilope LM. \u00bfEs \u00fatil calcular el riesgo cardiovascular a 30 a\u00f1os? Med Clin (Barc) 2014;142:540 -541 \n[AO,I]  \n24656124  \n\u00bfES \u00daTIL CALCULAR EL RIESGO CARDIOVASCULAR A 30 A\u00d1OS?  \n \nCatal\u00e1 -L\u00f3pez F, Hutton B, Moher D. Declaraci\u00f3n de transparencia para las publicaciones cient\u00edficas. Med Clin (Barc) \n2014;142:554 -555 [AO,II]  \n24703420  \nDECLARACI\u00d3N DE TRANSPARENCIA PARA LAS PUBLICACIONES CIENT\u00cdFICAS  \n \nREVISTA ESPA\u00d1OLA DE CARDIOLOGIA  \n \nFerreira -Gonz\u00e1lez I. Bases para la interpretaci\u00f3n de los estudios de no inferioridad: a prop\u00f3sito de los estudios \nROCKET \u2013AF, RE -LY y ARISTOTLE. Rev Esp Cardiol 2014;67:432 -435  [R,I]  \n24863590  R/C \nBASES PARA LA INTERPRETACI\u00d3N DE LOS ESTUDIOS DE NO INFERIORIDAD: A PROP\u00d3SITO DE LOS \nESTUDIOS ROCKET \u2013AF, RE -LY Y ARISTOTLE  \n  \n Vald\u00e9s S, Garc\u00eda -Torres F, Maldonado -Araque C, Goday A, Calle -Pascual A, Soriguer F, et al; Di@bet.es st udy group. \nPrevalencia de obesidad, diabetes mellitus y otros factores de riesgo cardiovascular en Andaluc\u00eda. Comparaci\u00f3n con \ndatos de prevalencia nacionales. Estudio Di@bet.es. Rev Esp Cardiol 2014;67:442 -448 [T,I]  \n24863592  R/C \nPREVALENCIA DE OBESIDAD, DIABETES MELLITUS Y OTROS FACTORES DE RIESGO CARDIOVASCULAR EN \nANDALUC\u00cdA. COMPARACI\u00d3N CON DATOS DE PREVALENCIA NACIONALES. ESTUDIO DI@BET.ES  \n \nGurbel PA, Rafeedheen R, Tantry US. Tratamiento antiagregante plaquetario personalizado. Rev Esp Cardiol \n2014;67:480 -487  [R,I]  \n24863597  R/C \nTRATAMIENTO ANTIAGREGANTE PLAQUETARIO PERSONALIZADO  \n \nSCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE  \n \nSigurdsson EL. Salt: a taste of death? Scand J Prim Health Care 2014;32:53 -54 [AO,I]  \n24939739   \nSAL \u00bfSABOR A MUERTE?  \n \nZand\u00e9n L, Bergh H. A home -based method for the detection of impaired glucose tolerance in hypertensive primary care \npatients. Scand J Prim Health Care 2014;32:62 -66 [T,I]  \n24779455   R/C \nM\u00c9TODO PARA LA DETECCI\u00d3N DOMICILIARIA DE TOLERANCIA ALTERADA A LA GLUCOSA EN PACIENTES \nHIPERTENSOS EN ATENCI\u00d3N PRIMARIA  \n \nKujanp\u00e4\u00e4 T, Ylisaukko -Oja T, Jokelainen J, Hirsikangas S, Kanste O, Kyng\u00e4s H, et al. Prevalence of anxie ty disorders \namong Finnish primary care high utilizers and validation of Finnish translation of GAD -7 and GAD -2 screening tools. \nScand J Prim Health Care 2014;32:78 -83 [T,I]  \n24920316   R/C \nPREVALENCIA DE TRASTORNOS DE ANSIEDAD ENTRE HIPERUTILIZADORES FINESES DE ATENCI\u00d3N \nPRIMARIA Y VALIDACI\u00d3N DE LA TRADUCCI\u00d3N FINESA DE LAS HERRAMIENTAS DE CRIBAJE GAD -7 Y GAD -2 \n \nNevalainen M, Kuikka L, Pitk\u00e4l\u00e4 K. Medical errors and uncerta inty in primary healthcare: A comparative study of coping \nstrategies among young and experienced GPs. Scand J Prim Health Care 2014;32:84 -89 [T,II]  \n24914458   R/C \nERRORES M\u00c9DICOS E INCERTIDUMBRE EN ATENCI\u00d3N PRIMARIA DE SALUD: ESTUDIO COMPARATIVO DE \nESTRATEGIAS DE SUPERACI\u00d3N ENTRE M\u00c9DICOS GENERALES TANTO J\u00d3VENES COMO EXPERIMENTADOS  \n \nKoffeman AR, Valkhoff VE, Jong GW, Warl\u00e9 -van Herwaarden MF, Bindels PJ, Sturkenboom M C, et al. Ischaemic \ncardiovascular risk and prescription of non -steroidal anti -inflammatory drugs for musculoskeletal complaints. Scand J \nPrim Health Care 2014;32:90 -98 [S,I]  \n24931511   R/C \nRIESGO CARDIOVASCULAR ISQU\u00c9MICO Y PRESCRIPCI\u00d3N DE AINE PARA LAS MOLESTIAS \nOSTEOMUSCULARES  \n \nTHE LANCET  \n \nHypertension: an urgent need for global control and prevention. Lancet 2014;383:1861 [AO,I]  \n24881973   \nHIPERTENSI\u00d3N: NECESIDAD URGENTE DE CONTROL Y PREVENCI\u00d3N MUNDIALES  \n \nPolio eradication: the CIA and their unintended victims. Lancet 2014;383:1862 [AO,I]  \n24881975   \nERRADICACI\u00d3N DE LA POLIO: LA C\u00cdA Y SUS V\u00cdCTIMAS NO INTENCIONADAS  \n \nWaeber B, Feihl F. Nebivolol and valsartan: useful treatment for hypertension? Lancet 2014;383:1864 -1866 [AO,I]  \n24881977   \nNEBIVOLOL Y VALSARTAN: TRATAMIENTO \u00daTIL PARA LA HIPERTENSI\u00d3N  \n \nKahan T. Focus on blood pressure as a major risk factor. Lancet 2014;383:1866 -1868.[AO,I]  \n24881978   \nCONCENTRARSE EN LA TENSI\u00d3N ARTERIAL COMO FACTOR DE RIESGO DE PRIMER ORDEN  \n \nMcManus RJ, Mant J. The drugs do work: blood pressure improvement in England. Lancet 2014;383:1868 -1869 [AO,I]  \n24881979   \nLAS MEDICINAS FUNCIONAN: MEJOR\u00cdA DE LA TEN SI\u00d3N ARTERIAL EN INGLATERRA  \n \nGiles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, et al; NAC -MD-01 Study Investigators. Efficacy and \nsafety of nebivolol and valsartan as fixed -dose combination in hypertension: a randomised, multicentre study. Lancet \n2014;383:1889 -1898 [EC,I]   \n 24881993   R/C \nEFICACIA Y SEGURIDAD DEL NEBIVOLOL Y EL VALSART AN COMO COMBINACI\u00d3N A DOSIS FIJA EN LA \nHIPERTENSI\u00d3N: ESTUDIO ALEATORIZADO MULTIC\u00c9NTRICO  \n \nRapsomaniki E, Timmis A, George J, Pujades -Rodriguez M, Shah AD, Denaxas  S, et al. Blood pressure and incidence \nof twelve cardiovascular diseases: lifetime risks, healthy life -years lost, and age -specific associations in 1\u00b725 million \npeople. Lancet 2014;383:1899 -1911 [S,II]  \n24881994   R/C \nTENSI\u00d3N ARTERIAL E INCIDENCIA DE DOCE ENFERMEDADES CARDIOVASCULARES: RIESGOS A LO LARGO \nDE LA VIDA, A\u00d1OS DE VIDA SANA PERDIDOS Y ASOCIACIONES ESPEC\u00cdFICAS POR EDAD EN 1,25 MILLONES \nDE PERSONAS  \n \nFalaschetti  E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross -sectional study from \n1994 to 2011. Lancet 2014;383:1912 -1919 [T,I]  \n24881995   R/C \nMANEJO DE LA HIPERTENSI\u00d3N EN INGLATERRA: ESTUDIO TRANSVERSAL SERIADO DESDE 1994 A 2011  \n \nBack to basics for diabetes. Lancet 2014;383:1945 [AO,I]  \n24910218   \nVUELTA A LOS PRINCIPIOS EN LA DIABETES  \n \nShi Y, Hu FB. The global implications of diabetes and cancer. Lancet 2014;383:1947 -1948 [AO,I]  \n24910221   \nIMPLICACIONES MUNDIALES DE LA DIABETES Y EL C\u00c1NCER  \n \nJi L. Sex disparity in the risk of diabetes -associated stroke. Lancet 2014;383:1948 -1950 [AO,I]  \n24613027  \nDISPARIDAD ENTRE SEXOS EN EL RIESGO DE ICTUS ASOCIADO A LA DIABETES   \n \nPeters SA, Huxley RR, W oodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic \nreview and meta -analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet 2014;383:1973 -1980 \n[M,II]  \n24613026   R/C \nDIABETES COMO FACTOR DE RIESGO PARA EL ICTUS EN MUJERES COMPARADAS CON HOMBRES: \nREVISI\u00d3N SISTEM\u00c1TICA Y METAAN\u00c1LISIS DE 64 COHORTES QUE INCLUYEN A 775.385 INDIVIDUOS Y 12.539 \nICTUS  \n \nDick KJ, Nelson CP, Tsaprouni L, Sandling JK, A\u00efssi D, Wahl S, et al. DNA methylation and body -mass index: a \ngenome -wide analysis. Lancet 2014;383:1990 -1998 [S,II]  \n24630777   R/C \nMETILACI\u00d3N DE ADN E \u00cdNDICE DE MASA CORPORAL: AN\u00c1LISIS GEN\u00d3MICO AMPLIO  \n \nLey SH, Hamdy O, Mohan V, Hu FB. Prevention and management of type 2 diabetes: dietary components and nutritional \nstrategies. Lancet 2014;383:1999 -2007 [R,I]  \n24910231   R/C \nPREVENCI\u00d3N Y MANEJO DE LA DIABETES TIPO 2: COMPONENTES DIET\u00c9TICOS Y ESTRATEGIAS \nNUTRICIONALES  \n \nThe World (fizzy drink) Cup 2014. Lancet 2014;383:2020 [AO,I]  \n24931680   \nLA COPA MUNDIAL 2014 (DE BEBIDA GASEOSA)  \n \nMigliori GB, Sotgiu G. Measuring the effect of tuberculosis control: a step forward. Lancet 2014;383:2026 -2028 [AO,I]  \n24650956   \nMEDIR EL EFECTO DEL CONTROL DE LA TUBERCULOSIS: UN PASO ADELANTE  \n \nTHE NEW ENGLAND JOURNAL OF MEDICINE  \n \nBoucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once -weekly dalbavancin versus daily \nconventional therapy for skin infection. N Engl J Med 2014;370:2169 -2179 [EC,I]  \n24897082   R/C \nDALBAVACINA UNA VEZ A LA SEMANA FRENTE AL TRATAMIENTO DIARIO CONVENCIONAL PARA LAS \nINFECCIONES DE LA PIEL  \n \nCorey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, et al; SOLO I Investigators. Single -dose oritavancin in \nthe treatment of acute bacterial skin infections. N Engl J Med 2014;370:21 80-2190 [EC,I]  \n24897083   R/C \nORITAVACINA EN DOSIS SIMPLE EN EL TRATAMIENTO DE LAS INFECCIONES D\u00c9RMICAS AGUDAS \nBACTERIANAS   \n  \nChirinos JA, Gurubhagavatula I, Teff K, Rade r DJ, Wadden TA, Townsend R, et al. CPAP, weight loss, or both for \nobstructive sleep apnea. N Engl J Med 2014;370:2265 -2275 [EC,I]  \n24918371   R/C \nCPAP, P\u00c9RDIDA DE PESO O AMBAS EN LA APNEA OBSTRUCTIVA DEL SUE\u00d1O  \n \nGottlieb DJ, Punjabi NM, Mehra R, Patel SR, Quan SF, Babineau DC, et al. CPAP versus oxygen in obstructive sleep \napnea. N Engl J Med 2014;370:2276 -2285 [EC,I]  \n24918372   R/C \nCPAP FRENTE A OX\u00cdGENO EN LA APNEA OBSTRUCTIVA DEL SUE\u00d1O  \n \nIngelfinger JR. Clinical practice. The child or adolescent with elevated blood pressure. N Engl J Med 2014;370:2316 -\n2325 [R,I]  \n24918374   \nPR\u00c1CTICA CL\u00cdNICA.  EL NI\u00d1O O ADOLESCENTE CON TENSI\u00d3N ARTERIAL ELEVADA  \n \nMacaraig M, Burzynski J, Varma JK. Tuberculosis control in New York City --a changing landscape. N Engl J Med \n2014;370:2362 -2365 [AO,I]  \n24941176   \nCONTROL DE LA TUBERCULOSIS EN LA CIUDAD DE NUEVA YORK -UN PAISAJE CAMBIANTE  \n \nHoberman A, Greenfield SP, Mattoo TK, Keren  R, Mathews R, Pohl HG, et al; RIVUR Trial Investigators. Antimicrobial \nprophylaxis for children with vesicoureteral reflux. N Engl J Med 2014;370:2367 -2376 [EC,I]  \n24795142   R/C \nPROFILAXIS ANTIMICROBIANA EN NI\u00d1OS CON REFLUJO VESICOURETERAL  \n \nChey WD, Webster L, Sostek M, Lappalainen J, Barker PN, Tack J. Naloxegol for opioid -induced constipation in patients \nwith noncancer pain. N Engl J Med 2014;370:2387 -2396 [EC,I]  \n24896818   R/C \nNALOXEGOL PARA EL ESTRE\u00d1IMIENTO INDUCIDO POR OPIOIDES EN PACIENTES CON DOLOR NO \nONCOL\u00d3GICO  \n \nHuybrechts KF, Palmsten K, Avorn  J, Cohen LS, Holmes LB, Franklin JM, et al. Antidepressant use in pregnancy and \nthe risk of cardiac defects. N Engl J Med 2014;370:2397 -2407 [S,II]  \n24941178   R/C \nUSO DE ANTIDEPRESIVOS EN EL EMBARAZO Y RIESGO DE DEFECTOS CARDIACOS  \n \nBiesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med 2014;370:2418 -2425 [R,I]  \n24941179   \nGENOMA DIAGN\u00d3STICO CL\u00cdNICO Y SECUENCIACI\u00d3N DE EXOMA  \n \nIngelfinger JR, Stapleton FB. Antibiotic prophylaxis for vesicoureteral reflux --answers, yet questions. N Engl J Med \n2014;370:2440 -2441 [AO,I]  \n2479514 3  \nPROFILAXIS ANTIBI\u00d3TICA EN EL REFLUJO VESICOURETERAL --RESPUESTAS, PERO TODAV\u00cdA PREGUNTAS  \n \nHwang TJ, Bourgeois FT, Seeger JD. Drug safety in the digital age. N Engl J Med 2014;370:2460 -2462 [AO,I]  \n24963564   \nSEGURIDAD FARMACOL\u00d3GICA EN LA ERA DIGITAL  \n \nConnors JM. Prophylaxis against venous thromboembolism in ambulatory patients with cancer. N Engl J Med \n2014;370:2515 -2519 [R,I]  \n24963570   \nPROFILAXIS CONTRA EL TROMBOEMBOLISMO VENOSO EN PACIENTES AMBULATORIOS CON C\u00c1NCER  \n \nCardiovascular morbidity and obstructive sleep apnea. N Engl J Med 2014 [Epub ahead of print] [AO,I]  \n24918956   \nMORBILIDAD CARDIOVASCULAR Y APNEA OBSTRUCTIVA DEL SUE\u00d1O  \n \n \nACADEMIC MEDICINE  \n \nS24662199  \nAll physicians take a leadership role at some point in their career -some exert influence in their practices and communities as informal \nleaders, and others hold formal leadership roles to which they are appointed or elected. These formal leadership roles c onvey power to \nthose individuals who hold such positions. Formal leadership, however, is limited in its influence unless it is accompanied b y a series of \npersonal and interpersonal competencies that characterize both formal and informal leaders.Many physic ians who do not hold formal \nleadership roles will be called on to provide (or will wish to provide) informal leadership at various times in their careers . Both formal and \ninformal leaders should be trained in the personal and interpersonal competencies nec essary for effective leadership to advance the \nprinciples -driven and values -oriented goals inherent in the health care enterprise.In this article, the author defines leadership and \ndescribes the characteristics of formal and informal leaders, then discusse s the types of leadership and the power derived from different  \n leadership roles. He concludes by arguing in favor of expanding the scope of leadership training to include informal as well as formal \nleaders.  \nS24871243  \nFindings suggest that important predic tors of physician performance on competence assessment include personal characteristics, \npractice context, and reasons for assessment referral. These findings have implications for development of policies and progr ams \ndesigned to assess risk of poor physic ian performance and quality of care improvement efforts through organizational/practice design or \nremedial education.  \n \nANNALS OF INTERNAL MEDICINE  \n \nS24862434  \nPrenatal HBV screening followed by postnatal prophylaxis is highly effective in preventing vertic al transmission of HBV. A negative e \nantigen status or a viral load less than 5 \u00d7 107 IU/mL (90.9% of women tested) identifies women at extremely low risk for tra nsmission \nafter immunoprophylaxis who are unlikely to benefit from further interventions.  \nS249 35489  \nThis synopsis of the guideline summarizes the evidence about risk factors for stroke in women and suggests prevention strateg ies. It \nalso describes the new recommendations relevant to identifying and treating hypertensive disorders in pregnancy that  increase risk for \nstroke.  \nS24887617   \nPharmacologic rate - and rhythm -control strategies have comparable efficacy across outcomes in primarily older patients with mild AF \nsymptoms. Pulmonary vein isolation is better than antiarrhythmic medications at reduc ing recurrences of AF in younger patients with \nparoxysmal AF and mild structural heart disease. Future research should address uncertainties related to subgroups of interes t and the \neffect of different therapies on long -term clinical outcomes.  \nS24887616  \nIn unscreened elderly persons CRC screening should be considered well beyond age 75 years. A colonoscopy is indicated at most \nages.  \nS24663815  \nThe USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for c ognitive \nimpairment. (I statement).  \n \nARCHIVOS DE BRONCONEUMOLOGIA  \n \nS24387877  \nEn estudios recientes ha quedando quedado perfectamente establecido que el tabaco incrementa la susceptibilidad a la infecci\u00f3n \nbacteriana pulmonar, incluso en fumadores pasivos. Este efecto muestra tambi\u00e9n dosis -respuesta, ya que disminuye \nespectacularmente el riesgo 10 a\u00f1os despu\u00e9s de abandonar e l h\u00e1bito tab\u00e1quico, situ\u00e1ndose a niveles de no fumadores.  \nStreptococcus pneumoniae es el microorganismo causante de neumon\u00eda adquirida en la comunidad (NAC) que m\u00e1s se ha relacionado \ncon el tabaquismo, especialmente en situaciones de enfermedad neumoc\u00f3cica  invasiva y shock s\u00e9ptico.  \nSu influencia sobre la evoluci\u00f3n de la neumon\u00eda no parece clara, aunque existen evidencias que sugieren un peor pron\u00f3stico de  la \nneumon\u00eda neumoc\u00f3cica.  \nEn NAC causadas por Legionella pneumophila tambi\u00e9n se ha observado que el h\u00e1bi to tab\u00e1quico es el factor de riesgo m\u00e1s remarcable, \nya que puede suponer un aumento del riesgo del 121% por cada paquete diario de cigarrillos consumidos.  \nPor otro lado, el consumo de tabaco puede tambi\u00e9n favorecer la presencia de enfermedades que a su vez  son factores de riesgo \nconocidos de NAC, como enfermedades periodontales e infecciones v\u00edricas de la v\u00eda a\u00e9rea superior.  \nComo medida preventiva, si bien cabe proponer el abandono del tabaco, tambi\u00e9n es recomendable la vacuna neumoc\u00f3cica, \nindependientement e de la presencia de comorbilidad.  \n \nATENCION PRIMARIA  \n \nS24768654  \nA pesar de la accesibilidad a la EF deben realizarse esfuerzos para estandarizar la formaci\u00f3n, incrementar el n\u00famero de explo raciones \ny promover el control de calidad sistem\u00e1tico.  \nS24768653  \nEl grado de satisfacci\u00f3n de los pacientes de atenci\u00f3n primaria domiciliaria parece depender de las caracter\u00edsticas propias de cada \nmodelo organizativo, siendo el modelo dispensarizado el que presenta un mayor grado de satisfacci\u00f3n o calidad asistencial per cibida. \nSe deber\u00eda realizar un mayor n\u00famero de estudios para generalizar estos resultados a otros centros de atenci\u00f3n primaria perten ecientes \na otras instituciones.  \nS24704194  \nEl cigarrillo electr\u00f3nico (e -cig) es un dispositivo con forma de cigarrillo conven cional que libera determinadas dosis de vapores de \nnicotina a trav\u00e9s de un proceso de calentamiento electr\u00f3nico.  \nLos cartuchos de nicotina tienen mucha variabilidad en la cantidad de nicotina liberada, incluso dentro de la misma marca. No  todas las \nmarcas admiten que contienen nicotina, pero esta se detecta en la mayor\u00eda de unidades analizadas. El e -cig contiene habitualmente \npropelentes como el propilenglicol, que es un producto irritante pulmonar. El efecto respiratorio a corto plazo del vapor de un e-cig es \nsimilar al causado por el humo del cigarrillo y es causa de broncoconstricci\u00f3n. La mayor\u00eda de marcas contienen glicerina, y s e ha \ndetectado al menos un caso de neumon\u00eda lipoidea por esta sustancia. Muchas marcas contienen trazas de N -nitrosaminas, meta les \npesados y otros productos que se encuentran en el humo de los cigarrillos convencionales en mucha mayor proporci\u00f3n. Actualmen te \nno se dispone de evidencia cient\u00edfica de que sea un dispositivo eficaz para dejar de fumar, por lo que no debe recomendarse de forma \nproactiva para este fin y puede interferir en el uso de tratamientos de evidencia cient\u00edfica demostrada para dejar de fumar. Puede tener \nun efecto indeseable al promover el inicio del consumo en adolescentes o retener a fumadores adultos en el con sumo de nicotina y en \nla dependencia gestual. No se conoce bien la toxicidad de los vapores pero se sabe que no son inocuos, por lo que no deber\u00edan  \nutilizarse en espacios p\u00fablicos cerrados.  \nS24661973  \nLa prescripci\u00f3n inapropiada en mayores es frecuente y es t\u00e1 relacionada con el uso de benzodiacepinas de vida media larga. Existen \ndiab\u00e9ticos con factores de riesgo cardiovascular en los que se omiten las estatinas. La polimedicaci\u00f3n juega un papel importa nte en las \nPPI y OP.  \nS24703389   \n El EAT -26 modificado y abr eviado es un instrumento multidimensional, con excelentes valores de confiabilidad y sensibilidad, y con un \nadecuado valor de especificidad, apropiado para el cribado de posible TCA en poblaci\u00f3n de riesgo y \u00fatil en atenci\u00f3n primaria para su \ndetecci\u00f3n tempr ana en mujeres j\u00f3venes.  \n \nBRITISH MEDICAL JOURNAL  \n \nS24865600  \nScreening for lung cancer with low dose computed tomography can reduce mortality from the disease by 20% in high risk smokers . This \nreview covers the state of the art knowledge on several aspects of implementing a screening program. The most important are to \nidentify people who are at high enough risk to warrant screening and the appropriate management of lung nodules found at scre ening. \nAn accurate risk prediction model is more efficient than age and pack years of smoking alone at identifying those who wil l develop lung \ncancer and die from the disease. Algorithms are available for assessing people who screen positive to determine who needs add itional \nimaging or invasive investigations. Concerns about low dose computed tomography screening include false posi tive results, \noverdiagnosis, radiation exposure, and costs. Further work is needed to define the frequency and duration of screening and to  refine \nrisk prediction models so that they can be used to assess the risk of lung cancer in special populations. Ano ther important area is the \nuse of computer vision software tools to facilitate high throughput interpretation of low dose computed tomography images so that costs \ncan be reduced and the consistency of scan interpretation can be improved. Sufficient data ar e available to support the implementation \nof screening programs at the population level in stages that can be expanded when found to perform well to improve the outcom e of \npatients with lung cancer.  \nWINDECKER  \nAmong patients with stable coronary artery dise ase, coronary artery bypass grafting reduces the risk of death, myocardial infarction, and \nsubsequent revascularisation compared with medical treatment. All stent based coronary revascularisation technologies reduce the \nneed for revascularisation to a vari able degree. Our results provide evidence for improved survival with new generation drug eluting \nstents but no other percutaneous revascularisation technology compared with medical treatment.  \nREES  \nLower urinary tract symptoms (LUTS) in men have many causes  and are often multifactorial  \nA full assessment helps in making a diagnosis and avoids the assumption that LUTS in all men are due to benign prostatic hype rplasia \n(BPH)  \nFrequency volume charts are underused but often provide important diagnostic clues  \nLifestyle measures, in particular altering fluid intake, can be useful for men with LUTS  \na blockers are the usual treatment for LUTS due to BPH, and antimuscarinics for overactive bladder  \n5 a reductase inhibitors reduce the risk of clinical progression and sho uld be targeted at those at high risk of clinical progression  \nA range of surgical options are available for men who fail initial medical management  \nLower urinary tract symptoms (LUTS) are common in men and increase in frequency and severity with age. Over one third of men aged \n50 or more are living with moderate to severe symptoms, equating to 3.4 million men in the United Kingdom alone and 24 millio n in \ncountries of the European Union.1 Most men with LUTS can be managed effectively in primary care, with ei ther conservative lifestyle \nmeasures or medical treatment.2 We discuss the causes of LUTS in men and summarise the current evidence on assessment and \nmanagement of patients  \nS24874977  \nHigher potency statin use is associated with a moderate increase in the r isk of new onset diabetes compared with lower potency statins \nin patients treated for secondary prevention of cardiovascular disease. Clinicians should consider this risk when prescribing  higher \npotency statins in secondary prevention patients.  \nS24906901  \nCommunity based specialist palliative care teams, despite variation in team composition and geographies, were effective at red ucing \nacute care use and hospital deaths at the end of life.  \nS24879819  \nThe effectiveness of thrombolytic therapy in daily clinical practice might be comparable with the effectiveness shown in randomised \nclinical trials and pooled analysis. Early treatment was associated with favourable outcome in daily clinical practice, which  underlines the \nimportance of speeding up the process for t hrombolytic therapy in hospital and before admission to achieve shorter time from door to \nneedle and from onset to treatment for thrombolytic therapy.  \nS24938302  \nDespite levels of 25(OH)D strongly varying with country, sex, and season, the association betwe en 25(OH)D level and all -cause and \ncause -specific mortality was remarkably consistent. Results from a long term randomised controlled trial addressing longevity are b eing \nawaited before vitamin D supplementation can be recommended in most individuals with low 25(OH)D levels.  \nS24899650  \nClinical study reports contained extensive data on major harms that were unavailable in journal articles and in trial registr y reports. \nThere were inconsistencies between protocols and clinical study reports and within clinica l study reports. Clinical study reports should \nbe used as the data source for systematic reviews of drugs, but they should first be checked against protocols and within the mselves for \naccuracy and consistency.  \nS24942789  \nSafety warnings about antidepressant s and widespread media coverage decreased antidepressant use, and there were simultaneous \nincreases in suicide attempts among young people. It is essential to monitor and reduce possible unintended consequences of F DA \nwarnings and media reporting.  \nS2494238 8 \nThis study found no evidence for a positive association between the use of drug treatments for ADHD and the risk of concomita nt \nsuicidal behaviour among patients with ADHD. If anything, the results pointed to a potential protective effect of drugs for A DHD on \nsuicidal behaviour, particularly for stimulant drugs. The study highlights the importance of using within patient designs to control for \nconfounding in future pharmacoepidemiological studies.  \nS24868083  \nAmong this well treated primary care population,  fixed dose combination treatment improved adherence to the combination of all \nrecommended drugs but improvements in clinical risk factors were small and did not reach statistical significance. Acceptabil ity was high \nfor both general practitioners and pati ents, although the discontinuation rate was high.  \nS24912589  \nA community based, individually tailored intervention programme with screening for risk of ischaemic heart disease and repeat ed \nlifestyle intervention over five years had no effect on ischaemic he art disease, stroke, or mortality at the population level after 10 \nyears.Trial registration Clinical trials NCT00289237.  \nS24951459  \nInvitation to modern mammography screening may reduce deaths from breast cancer by about 28%.   \n  \nBRITISH JOURNAL OF PSYCHIATRY  \n \nS24676963  \nContinuing CST improves quality of life; and improves cognition for those taking AChEIs.  \nS24676966  \nHigh levels of early childhood conduct problems are particularly associated with increased health, social care and criminal j ustice costs \nin adul thood.  \nS24578445  \nSuicide risk in physically ill people varies substantially by presence of psychiatric comorbidity, particularly the relative timing of onset of \nthe two types of illness. Closer collaboration between general and mental health services shoul d be an essential component of suicide \nprevention strategies.  \nS24526745  \nBoth interventions led to significant reductions in long -term benzodiazepine use in patients without severe comorbidity. A structured \nintervention with a written individualised stepped -dose reduction is less time -consuming and as effective in primary care as a more \ncomplex intervention involving follow -up visits.  \n \nCANADIAN MEDICAL ASSOCIATION JOURNAL  \n \nS24664649  \nIn this trial, the rate of successful radial -head subluxation performed by nurses was inferior to the physician success rate. Although the \nsuccess rate in the nurse -initiated care group did not meet the non -inferiority margin, nurses were able to reduce radial head \nsubluxation for almost 85% of children who presented with probabl e radial -head subluxation. Trial registration: Clinical Trials.gov, no. \nNCT00993954.  \nS24756625  \nWe found robust associations between child abuse and mental conditions. Health care providers, especially those assessing pat ients \nwith mental health problems, n eed to be aware of the relation between specific types of child abuse and certain mental conditions. \nSuccess in preventing child abuse could lead to reductions in the prevalence of mental disorders, suicidal ideation and suici de attempts.  \n \nCIRCULATION  \n \nS24842943  \nHospitalization rates for AF have increased exponentially among US adults from 2000 to 2010. The proportion of comorbid chron ic \ndiseases has also increased significantly. The last decade has witnessed an overall decline in hospital mortality; how ever, the \nhospitalization cost has significantly increased.  \nS24799511  \nA well -established body of scientific research shows that there is a strong relationship between excess sodium intake and high blood  \npressure and other adverse health outcomes. With Amer icans getting >75% of their sodium from processed and restaurant food, this \nevidence creates mounting pressure for less sodium in the food supply. The reduction of sodium in the food supply is a comple x issue \nthat involves multiple stakeholders. The succes s of new technological approaches for reducing sodium will depend on product \navailability, health effects (both intended and unintended), research and development investments, quality and taste of refor mulated \nfoods, supply chain management, operational mo difications, consumer acceptance, and cost. The conference facilitated an exchange of \nideas and set the stage for potential collaboration opportunities among stakeholders with mutual interest in reducing sodium in the food \nsupply and in Americans' diets. P opulation -wide sodium reduction remains a critically important component of public health efforts to \npromote cardiovascular health and prevent cardiovascular disease and will remain a priority for the American Heart Associatio n. \n \nDIABETES CARE  \n \nS24855154  \nGiven the continued interest in defining the optimal management of individuals with type 2 diabetes, the Editor of Diabetes Ca re \nconvened a working party of diabetes specialists to examine this topic in the context of insulin therapy. This was prompted b y recent \nnew evidence on the use of insulin in such people. The group was aware of evidence that the benefits of insulin therapy are s till usually \noffered late, and thus the aim of the discussion was how to define the optimal timing and basis for decisions re garding insulin and to \napply these concepts in practice. It was noted that recent evidence had built upon that of the previous decades, together con firming the \nbenefits and safety of insulin therapy, albeit with concerns about the potential for hypoglycemi a and gain in body weight. Insulin offers a \nunique ability to control hyperglycemia, being used from the time of diagnosis in some circumstances, when metabolic control is \ndisturbed by medical illness, procedures, or therapy, as well as in the longer term in ambulatory care. For those previously starting \ninsulin, various other forms of therapy can be added later, which offer complementary effects appropriate to individual needs . Here we \nreview current evidence and circumstances in which insulin can be used,  consider individualized choices of alternatives and \ncombination regimens, and offer some guidance on personalized targets and tactics for glycemic control in type 2 diabetes.  \nS24595629  \nIn the ACCORD BP trial, compared with combined standard treatment, in tensive BP or intensive glycemia treatment alone improved \nmajor CVD outcomes, without additional benefit from combining the two. In the ACCORD lipid trial, neither intensive lipid nor  glycemia \ntreatment produced an overall benefit, but intensive glycemia t reatment increased mortality.  \nS24705610  \nThe presence of a minor lesion was clearly the strongest predictor, while recommended use of adequately offloading footwear w as a \nstrong protector against ulcer recurrence from unrecognized repetitive trauma. These o utcomes define clear targets for diabetic foot \nscreening and ulcer prevention.  \nS24667462  \nAlthough measuring SMB is difficult and the used operationalization might be limited, our results give some indication that a  high level of \nSMB is associated with prol onged life expectancy in patients with type 2 diabetes and highlight the potential impact of the patients' \nactive contribution on the long -term trajectory of the disease. We assume that the used proxy for SMB is associated with unmeasured, \nbut important, d imensions of health behavior.  \nS24705609  \nThe incidence of both GDM and pre -GDM in pregnancy has doubled over the last 14 years, and the overall burden of diabetes in \npregnancy on society is growing. Although congenital anomaly rates have declined in women w ith diabetes, perinatal mortality rates \nremain unchanged, and the risk of both remains significantly elevated compared with nondiabetic women. Increased efforts are needed \nto reduce these adverse outcomes.   \n S24855158  \nComputer -based diabetes self -management interventions to manage type 2 diabetes appear to have a small beneficial effect on blood \nglucose control, and this effect was larger in the mobile phone subgroup. There was no evidence of benefit for other biologic al, \ncognitive, behavioral, or emotional o utcomes.  \nS24722494  \nEmpagliflozin 10 and 25 mg for 24 weeks as add -on to metformin therapy significantly improved glycemic control, weight, and BP, and \nwere well -tolerated.  \nS24855159  \nThe availability of insulin analogs has offered insulin replacement strategies that are proposed to more closely mimic normal  human \nphysiology. Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, as part, glulisine) \nhave pharmacokinetic and pharmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when \ncompared with regular human insulin. In addition, basal insulin analogs (glargine, detemir) have been reporte d to offer longer duration of \naction, less variability, more predictability, less hypoglycemia (especially nocturnal), and a favorable effect on weight. Ho wever, an \nargument against use of analog insulins as compared with use of regular or NPH insulin is o ne that states that the effectiveness and risk \nof hypoglycemia are the only two valid clinical outcomes that should be used to compare the analog and human insulins. Thus, there \nremains a debate in some circles that analog insulins are no more effective th an human insulins, yet at a much higher financial cost. To \nprovide an in -depth understanding of both sides of the argument, we provide a discussion of this topic as part of this two -part point -\ncounterpoint narrative. In the counterpoint narrative, Dr. Davi dson provides his argument and defends his opinion that outside of a few \nexceptions, analog insulins provide no clinical benefit compared with human insulins but cost much more. In the point narrati ve \npresented here, Dr. Grunberger provides a defense of an alog insulins and their value in clinical management and suggests that when \nevaluating the \"cost\" of therapy, a much more global assessment is needed. -William T. CefaluEditor in Chief, Diabetes Care.  \nS24855160  \nThe availability of insulin analogs has offer ed insulin replacement strategies that are proposed to more closely mimic normal human \nphysiology. Specifically, there are a considerable number of reports demonstrating that prandial insulin analogs (lispro, asp art, glulisine) \nhave pharmacokinetic and pha rmacodynamic profiles closer to normal, with resulting faster onset and offset of insulin effect when \ncompared with regular human insulin. In addition, basal insulin analogs (glargine, detemir) have been reported to offer longe r duration of \naction, less va riability, more predictability, less hypoglycemia (especially nocturnal), and a favorable effect on weight. However, an \nargument against use of analog insulins as compared with use of regular or NPH insulin is one that states that the effectiven ess and ris k \nof hypoglycemia are the only two valid clinical outcomes that should be used to compare the analog and human insulins. Thus, there \nremains a debate in some circles that analog insulins are no more effective than human insulins, yet at a much higher finan cial cost. To \nprovide an in -depth understanding of both sides of the argument, we provide a discussion of this topic as part of this two -part point -\ncounterpoint narrative. In the counterpoint narrative presented here, Dr. Davidson provides his argument and  defends his opinion that \noutside of a few exceptions, analog insulins provide no clinical benefit compared with human insulins but cost much more. In the \npreceding point narrative, Dr. Grunberger provides a defense of analog insulins and their value in cl inical management and suggests \nthat when evaluating the \"cost\" of therapy, a much more global assessment is needed. -William T. CefaluEditor in Chief, Diabetes Care.  \n \nDRUGS  \n \nS24825489  \nRecent high -quality studies have confirmed the central role of lithium in the treatment of bipolar disorder and have established lithium as \nthe drug of first choice for long -term prophylaxis in this condition. However, several indications for its use in un ipolar major depression \nare also based on sound evidence. This includes lithium augmentation as a main strategy for depressed patients not responding  to an \nantidepressant, lithium prophylaxis for recurrent unipolar depression as an alternative to prophylax is with an antidepressant, and \nlithium's unique anti -suicidal properties. Lithium monotherapy, on the other hand, is not established for acute treatment of depression. \nLithium therapy should be a core competency of every psychiatrist, enabling the safe use  of lithium, to the benefit of our patients.  \nS24866023  \nThe epoch -making discovery of insulin heralded a new dawn in the management of diabetes. However, the earliest, unmodified soluble \ninsulin preparations were limited by their short duration of action,  necessitating multiple daily injections. Initial attempts to protract the \nduration of action of insulin involved the use of various additives, including vasoconstrictor substances, which met with lim ited success. \nThe subsequent elucidation of the chemical  and three -dimensional structure of insulin and its chemical synthesis and biosynthesis \nallowed modification of the insulin molecule itself, resulting in insulin analogs that are designed to mimic normal endogenou s insulin \nsecretion during both fasting and  prandial conditions. Insulin glargine was the first once -daily, long -acting insulin analog to be introduced \ninto clinical practice more than 10 years ago and is specifically designed to provide basal insulin requirements. It has a pr olonged \nduration of ac tion and no distinct insulin peak, making it suitable for once -daily administration and reducing the risk of nocturnal \nhypoglycemia that is seen with intermediate -acting insulins. Insulin glargine can be used in combination with prandial insulin \npreparatio ns and non -insulin anti -diabetic agents according to individual requirements.  \nS24846578  \nTuberculosis (TB) is the world's second leading infectious killer. Cases of multidrug -resistant (MDR -TB) and extremely drug -resistant \n(XDR -TB) have increased globally . Therapeutic drug monitoring (TDM) remains a standard clinical technique for using plasma drug \nconcentrations to determine dose. For TB patients, TDM provides objective information for the clinician to make informed dosi ng \ndecisions. Some patients are slo w to respond to treatment, and TDM can shorten the time to response and to treatment completion. \nNormal plasma concentration ranges for the TB drugs have been defined. For practical reasons, only one or two samples are col lected \npost-dose. A 2 -h post -dose sample approximates the peak serum drug concentration (Cmax) for most TB drugs. Adding a 6 -h sample \nallows the clinician to distinguish between delayed absorption and malabsorption. TDM requires that samples are promptly cent rifuged, \nand that the serum is promptly harvested and frozen. Isoniazid and ethionamide, in particular, are not stable in human serum at room \ntemperature. Rifampicin is stable for more than 6 h under these conditions. Since our 2002 review, several papers regarding T B drug \npharmacokinet ics, pharmacodynamics, and TDM have been published. Thus, we have better information regarding the concentrations \nrequired for effective TB therapy. In vitro and animal model data clearly show concentration responses for most TB drugs. Rec ent \nstudies empha size the importance of rifamycins and pyrazinamide as sterilizing agents. A strong argument can be made for maximizing \npatient exposure to these drugs, short of toxicity. Further, the very concept behind 'minimal inhibitory concentration' (MIC)  implies tha t \none should achieve concentrations above the minimum in order to maximize response. Some, but not all clinical data are consis tent with \nthe utility of this approach. The low ends of the TB drug normal ranges set reasonable 'floors' above which plasma conc entrations \nshould be maintained. Patients with diabetes and those infected with HIV have a particular risk for poor drug absorption, and  for drug -\ndrug interactions. Published guidelines typically describe interactions between two drugs, whereas the clinica l situation often is \nconsiderably more complex. Under 'real -life' circumstances, TDM often is the best available tool for sorting out these multi -drug \ninteractions, and for providing the patient safe and adequate doses. Plasma concentrations cannot explain  all of the variability in patient \nresponses to TB treatment, and cannot guarantee patient outcomes. However, combined with clinical and bacteriological data, T DM can \nbe a decisive tool, allowing clinicians to successfully treat even the most complicated T B patients.   \n S24902800  \nTrimetazidine is a cytoprotective drug whose cardiovascular effectiveness, especially in patients with stable ischemic heart disease, has \nbeen the source of much controversy in recent years; some have gone so far as to treat the med ication as a 'placebo drug' whose new \nside effects, such as Parkinsonian symptoms, outweigh its benefits. This article is an attempt to present the recent key stud ies, including \nmeta -analyses, on the use of trimetazidine in chronic heart failure, also in p atients with diabetes mellitus and arrhythmia, as well as in \nperipheral artery disease. This paper also includes the most recent European Society of Cardiology guidelines, including thos e of 2013, \non the use of trimetazidine in cardiovascular disease.  \nS24866024  \nApproximately 30 % of HIV -infected patients are co -infected with hepatitis C virus (HCV). After the release of highly active antiretroviral \ntherapy, liver disease has become the leading cause of morbidity and mortality in HIV patients. Prior to 201 1, HCV treatment with \npegylated -interferon and ribavirin in HCV/HIV co -infected patients only allowed 14 -38 % of patients with HCV genotype 1 to achieve a \nsustained virologic response (SVR). Additionally, treatment was commonly discontinued as a result of adverse events. Recently, \nsimeprevir and sofosbuvir have been approved by the US Food and Drug Administration (FDA) for HCV mono -infection. Sofosbuvir has \nbeen given FDA approval in co -infected patients offering unprecedented SVR rates and the potential fo r interferon -free therapy. HCV \ntherapies that are in the pipeline offer improved treatment times, safety profiles, and rates of SVR. Despite these improveme nts, several \nnew issues including adherence, drug -drug interactions with antiretroviral therapies, a dverse events, resistance, and patient selection \nmay complicate therapy. This article reviews the current status of direct -acting antivirals (DAA) -containing regimens for HIV/HCV co -\ninfected patients in the USA. New results investigating telaprevir and boc eprevir are also discussed as they are relevant for locations \nwhere new DAAs are not available. The impact future interferon -free therapies may have on co -infected patients is also discussed.  \n \nEUROPEAN HEART JOURNAL  \n \nS24057077  \nSelf-reported symptoms of de pression and anxiety, especially if recurrent, were moderately associated with the risk of incident AMI. We \nhad some indications that these associations might partly reflect reverse causation or confounding from common chronic diseas es. \nS24639425  \nAtrial fi brillation (AF) is the most common arrhythmia and has gained increasingly more attention due to new treatment options, \nparticularly catheter ablation. Growing experience with this technique and better AF suppression compared with antiarrhythmic  \nmedication have paved the way for its extended use and indication. At this point, it is recommended for symptomatic patients if \nantiarrhythmic drugs failed and in selected young symptomatic patients as first line therapy. It is a tempting concept to imp rove \nprognosis  in young AF patients by rhythm control irrespective of symptoms. In this review, we summarize epidemiological data on young \nAF, efficacy, and limitations of rate and rhythm control by means of medication and catheter ablation in young patients, info rmatio n on \narrhythmia progression and outcome, and the consequences of these data for AF treatment in young, asymptomatic patients.  \nS24282187  \nCardiovascular disease (CVD) and depression are common. Patients with CVD have more depression than the general populati on. \nPersons with depression are more likely to eventually develop CVD and also have a higher mortality rate than the general popu lation. \nPatients with CVD, who are also depressed, have a worse outcome than those patients who are not depressed. There is a g raded \nrelationship: the more severe the depression, the higher the subsequent risk of mortality and other cardiovascular events. It  is possible \nthat depression is only a marker for more severe CVD which so far cannot be detected using our currently availab le investigations. \nHowever, given the increased prevalence of depression in patients with CVD, a causal relationship with either CVD causing mor e \ndepression or depression causing more CVD and a worse prognosis for CVD is probable. There are many possible p athogenetic \nmechanisms that have been described, which are plausible and that might well be important. However, whether or not there is a  causal \nrelationship, depression is the main driver of quality of life and requires prevention, detection, and manageme nt in its own right. \nDepression after an acute cardiac event is commonly an adjustment disorder than can improve spontaneously with comprehensive \ncardiac management. Additional management strategies for depressed cardiac patients include cardiac rehabilita tion and exercise \nprogrammes, general support, cognitive behavioural therapy, antidepressant medication, combined approaches, and probably dise ase \nmanagement programmes.  \nS24536084  \nAtrial  fibrillation (AF) is generally considered a progressive disease, typically evolving from paroxysmal through persistent to 'pe rmanent' \nforms, a process attributed to electrical and structural remodelling related to both the underlying disease and AF itself . Medical \ntreatment has yet to demonstrate clinical efficacy in preventing progression. Large clinical trials performed to date have fa iled to show \nbenefit of rhythm control compared with rate control, but these trials primarily included patients at late s tages in the disease process. \nOne possible explanation is that intervention at only an early stage of progression may improve prognosis. Evolving observati ons about \nthe progressive nature of AF, along with the occurrences of major complications such as str okes upon AF presentation, led to the notion \nthat earlier and more active approaches to AF detection, rhythm -reversion, and maintenance of sinus rhythm may be a useful strategy in \nAF management. Approaches to early and sustained rhythm control include meas ures that prevent development of the AF substrate, \nearlier catheter ablation, and novel antiarrhythmic drugs. Improved classifications of AF mechanism, pathogenesis, and remode lling \nmay be helpful to enable patient -specific pathophysiological diagnosis and  therapy. Potential novel therapeutic options under \ndevelopment include microRNA -modulation, heatshock protein inducers, agents that influence Ca2+ handling, vagal stimulators, and \nmore aggressive mechanism -based ablation strategies. In this review, of res earch into the basis and management of AF in acute and \nearly settings, it is proposed that progression from paroxysmal to persistent AF can be interrupted, with potentially favoura ble prognostic \nimpact.  \nS24591550  \nThere is a higher risk of cardiovascular ev ents shortly after outbursts of anger.  \n \nFAMILY MEDICINE  \n \nS24911300  \nOur findings show that primary care hypertension patients who use a lipophilic beta -blocker are more likely to have higher depression \nscores than those who do not use a lipophilic beta -blocker.  \nS24911299  \nSuccessful implementation of innovative PCMH curricula is key  to preparing a workforce ready to practice in a new model of health care \ndelivery. This qualitative study demonstrates that an experiential PCMH curriculum can enhance third -year medical student self -\nassessed knowledge of and attitudes toward the PCMH and  may improve perceptions of a career in primary care.  \nS24911296  \nDespite increased emphasis on quality improvement activities in practice, most family medicine clerkships do not currently of fer PBLI \ncurricula. Additionally, less than one in four family med icine clerkships plan on increasing the amount of PBLI curricula in the next 12 \nmonths. Continued research in this area is needed to identify successful models for PBLI curricular offerings.   \n S24911298  \nA successful curriculum redesign requires considerable  planning and coordination. We designed and implemented a comprehensive \nCSC that was both well received and effective. Peer teaching programs can provide medical education leadership experiences wi th \nbenefits for learners, teachers, and medical educators.  \n \nFAMILY PRACTICE  \n \nS24435069  \nBased on a literature search and expert opinion, we have developed an information leaflet for GPs to provide as a supplement to oral \nshoe advice. Women using this leaflet were able to select shoes of better quality and better fi t than women selecting shoes without \nusing the leaflet.  \nS24639564  \nThe data showed high levels of involvement by German PCPs in CVD prevention and dietary counselling. The rather low perceived  \nsuccess of dietary intervention and differences with respect to patients' health insurance status indicate a need to address both \ncommunication skills in medical training and appropriate reimbursement of preventive services.  \nS24736294  \nAlthough the findings are in favour of purposeful selection, observed differences in detected problems between the two selection \nprocedures are relatively small. GPs should at least target older people with =2 chronic conditions, using =5 medications, be ing female, \nof an older age, living alone and the less educated.  \nS24728774  \nStroke risk profiles of patients detected via opportunistic and systematic screenings were similar. Data derived from the SAF E study \nsuggest that active screening for AF in patients aged =65 years in primary care is a useful screening programme with 78 -83% of \npatients identified eligible for anticoagulation treatment according to the CHADS2 criteria.  \nS24736295  \nThis study has elucidated specific costs, benefits and ethical barriers to placebo use as perceived by a large sample of UK G Ps. Stand -\nalone qualitat ive work would provide a more in -depth understanding of GPs' views. Continuing education and professional guidance \ncould help GPs update and contextualize their understanding of placebos and their clinical effects.  \nS24532609  \nOur study shows a high burden o f care for fall -related injuries in older general practice patients and provides baseline data for its future \nmonitoring.  \nS24367069  \nThe use of implementation strategies for the distribution of guidelines on CVD can be convincingly effective on physician ad herence, \nregardless whether based on a unimodal or multimodal design. Three distinct strategies should be well considered in such an a ttempt: \norganizational changes in the primary care team, patient education and provider education.  \nS24473676  \nThe Stepping Up model allowed technical care to be embedded within generalist whole -person care, supported clinicians and practice \nsystem to overcome clinical inertia and supported patients to make the timely transition to insulin. Testing of the model's e ffectiveness is \nnow underway.  \nS24621557  \nClear, comprehensive criteria, particularly with regards to comorbidities, are required for GPs to confidently screen patient s for potential \nparticipation in research. Future studies should promote inclusivity and encourage GPs t o adopt a liberal approach when screening \npatient lists. This would enhance the validity and generalizability of primary care research and encourage greater patient au tonomy.  \n \nJOURNAL OF THE AMERICAN MEDICAL ASSOCIATION  \n \nS24915260  \nAmong patients with diabetes who were receiving metformin, the addition of insulin vs a sulfonylurea was associated with an i ncreased \nrisk of a composite of nonfatal cardiovascular outcomes and all -cause mortality. These findings require further investigat ion to \nunderstand risks associated with insulin use in these patients.  \nS24915263  \nInsulin can help achieve ideal hemoglobin A1c goals for patients with type 2 diabetes. Barriers such as adherence, patient pr eferences, \nclinician preferences, and resource al location must be addressed.  \nS24893088  \nAmong Medicare beneficiaries hospitalized for heart failure and with an LVEF between 30% and 35% and less than 30%, survival at 3 \nyears was better in patients who received a prophylactic ICD than in comparable patient s with no ICD. These findings support guideline \nrecommendations to implant prophylactic ICDs in eligible patients with an LVEF of 35% or less.  \nS24893087  \nAmong older patients hospitalized with pneumonia, treatment that included azithromycin compared with o ther antibiotics was associated \nwith a lower risk of 90 -day mortality and a smaller increased risk of myocardial infarction. These findings are consistent with a net \nbenefit associated with azithromycin use.  \nS24892770  \nDeclines in estimated GFR smaller than a doubling of serum creatinine concentration occurred more commonly and were strongly and \nconsistently associated with the risk of ESRD and mortality, supporting consideration of lesser declines in estimated GFR (su ch as a \n30% reduction over 2 years) as an alternative end point for CKD progression.  \nS24866862  \nA structured, moderate -intensity physical activity program compared with a health education program reduced major mobility disability \nover 2.6 years among older a dults at risk for disability. These findings suggest mobility benefit from such a program in vulnerable older \nadults.  \nS24938566  \nCLINICAL QUESTION:  \nIs exercise an effective treatment for depression?  \nBOTTOM LINE:  \nExercise is associated with a greater redu ction in depression symptoms compared with no treatment, placebo, or active control \ninterventions, such as relaxation or meditation. However, analysis of high -quality studies alone suggests only small benefits.  \nS24893090  \nCLINICAL QUESTION Is prophylactic antibiotic treatment associated with fewer exacerbations or improved health -related quality of life \n(HRQOL) in patients with chronic obstructive pulmonary disease (COPD)? BOTTOM LINE Continuous macrolide antibiotic use for  \n prophylaxis was associated with a  clinically significant reduction in COPD exacerbations. Pulsed antibiotic use was not associated with \nbenefit. Continuous and pulsed antibiotics were associated with improved HRQOL, but this was not clinically significant.  \nS24893089  \nResistant hypertensi on-uncontrolled hypertension with 3 or more antihypertensive agents -is increasingly common in clinical practice. \nClinicians should exclude pseudoresistant hypertension, which results from nonadherence to medications or from elevated blood  \npressure related to the white coat syndrome. In patients with truly resistant hypertension, thiazide diuretics, particularly chlorthalidone, \nshould be considered as one of the initial agents. The other 2 agents should include calcium channel blockers and angiotensin -\nconver ting enzyme inhibitors for cardiovascular protection. An increasing body of evidence has suggested benefits of mineralocortic oid \nreceptor antagonists, such as eplerenone and spironolactone, in improving blood pressure control in patients with resistant \nhypertension, regardless of circulating aldosterone levels. Thus, this class of drugs should be considered for patients whose bl ood \npressure remains elevated after treatment with a 3 -drug regimen to maximal or near maximal doses. Resistant hypertension may be  \nassociated with secondary causes of hypertension including obstructive sleep apnea or primary aldosteronism. Treating these d isorders \ncan significantly improve blood pressure beyond medical therapy alone. The role of device therapy for treating the typica l patient with \nresistant hypertension remains unclear.  \nOMEARA  \nClinical Question:  Is treatment with topical or systemic antimicrobial agents associated with better venous leg ulcer healin g compared \nwith usual care (dressings and bandages without antimicrob ials) or an alternative topical or systemic antimicrobial agent?  \nBottom Line:  Available evidence, from underpowered pooled data, neither supports nor refutes an association of systemic anti biotic \ntherapy with improved venous leg ulcer healing. Among topic al antimicrobials, cadexomer iodine may be associated with better healing \ncompared with usual care.  \nPISANO  \nAnother spirited debate has ensued over the benefits of breast cancer screening,1 freshly stimulated by the recent publicatio n of the 25 -\nyear follow -up results of the Canadian National Breast Screening Study (CNBSS) that showed no difference in breast cancer\u00e2\u20ac\u2015related \nmortality in screened women vs controls.2 This latest controversy developed even though the CNBSS is the only one of 8 random ized \nclinic al trials of screening mammography that failed to find a reduction in mortality,3 and despite substantial and well -described \nlimitations in the CNBSS methods,4 including poor image quality and problems in the randomization schema that created a scree ned \ncohort with more large palpable cancers than the control group. Fourteen more recent studies published between 2001 and 2010 us ing \nmore modern technology have shown a 25% to 50% reduction in breast cancer\u00e2\u20ac\u2015related mortality for women aged 40 to 74 years.5  In \nthe interval since the randomized trials of screening and with the demonstration of improved diagnostic accuracy for women wi th dense \nbreasts,6 digital mammography has supplanted film mammography as the screening technology of choice,7 and treatment of b reast \ncancer has improved substantially.8  \nFRIEDEWALD  \nAddition of tomosynthesis  to digital mammography was associated with a decrease in recall rate and an increase in cancer detection \nrate. Further studies are needed to assess the relationship to clinical outcomes  \n \nJAMA INTERNAL MEDICINE  \n \nS24733354  \nDirect -to-consumer education effectively elicits shared decision making around the overuse of medications that increase the risk of har m \nin older adults. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01148186.  \nS24756610  \nFalse -positive mammograms w ere associated with increased short -term anxiety but not long -term anxiety, and there was no \nmeasurable health utility decrement. False -positive mammograms increased women's intention to undergo future breast cancer \nscreening and did not increase their sta ted willingness to travel to avoid a false -positive result. Our finding of time -limited harm after \nfalse -positive screening mammograms is relevant for clinicians who counsel women on mammographic screening and for screening \nguideline development groups.  \nS24710960  \nSildenafil use may be associated with an increased risk of developing melanoma. Although this study is insufficient to alter clinical \nrecommendations, we support a need for continued investigation of this association.  \nS24733277  \nA novel telephon e-based, low -intensity model to concurrently manage cardiac patients with depression and/or anxiety disorders was \neffective for improving mental health -related quality of life in a 24 -week trial. TRIAL REGISTRATION clinicaltrials.gov Identifier: \nNCT0120196 7.  \n \nJAMA PSYCHIATRY  \n \nS24789675  \nMany pharmacotherapies and psychotherapies are effective, but there is a lot of room for improvement. Because of the multiple  \ndifferences in the methods used in pharmacotherapy and psychotherapy trials, indirect comparisons  of their effect sizes compared with \nplacebo or no treatment are problematic. Well -designed direct comparisons, which are scarce, need public funding. Because patients \noften benefit from both forms of therapy, research should also focus on how both modalit ies can be best combined to maximize synergy \nrather than debate the use of one treatment over the other.  \n \nMEDICINA CLINICA  \n \nS24387955  \nLa comorbilidad FM empeora los par\u00e1metros cl\u00ednicos, la fatiga y la percepci\u00f3n de la calidad de vida en los pacientes con SFC.  \nS23622897  \nAproximadamente la mitad de los pacientes con DM2 no insulinizados y en tratamiento con HO presenta ICP. Cuatro de cada 10 \npacientes cumplen adecuadamente el tratamiento con HO. El sexo femenino y una menor duraci\u00f3n de la DM2 se asocian \nindependientemente a ICP.  \nS24183117  \nEl exceso de peso es un grave problema de salud p\u00fablica, con una importante mortalidad asociada. El an\u00e1lisis de los fallecimi entos \natribuibles es una \u00fatil herramienta para conocer la situaci\u00f3n real y la monitorizaci\u00f3n de las  medidas encaminadas a su control.  \nS23683969  \nLa DM2 se asocia a sobrepeso y obesidad y aumenta con el grado de IMC. Dislipidemia, hipertensi\u00f3n y sedentarismo en DM2 se \nincrementan con el aumento del IMC. Los pacientes con peor control metab\u00f3lico se asocian  a mayor grado de obesidad.  \nS24480288   \n La encefalopat\u00eda hep\u00e1tica (EH) es una complicaci\u00f3n frecuente de la cirrosis, con un gran impacto social, que deteriora la cal idad de \nvida del paciente y se considera un signo de enfermedad hep\u00e1tica avanzada y, por tant o, una indicaci\u00f3n cl\u00ednica para la evaluaci\u00f3n de \ntrasplante hep\u00e1tico.  \nLos pacientes que han presentado episodios de EH tienen un elevado riesgo de recurrencia, por lo que una vez superado el epis odio \nde EH se recomienda el control y la prevenci\u00f3n de factore s precipitantes (hemorragia digestiva, peritonitis bacteriana espont\u00e1nea, uso \nde los diur\u00e9ticos con precauci\u00f3n, evitar medicaci\u00f3n depresora del sistema nervioso), la administraci\u00f3n continuada de disac\u00e1ri dos no \nabsorbibles, como lactitol o lactulosa, o de a ntibi\u00f3ticos poco o no absorbibles como rifaximina, y la valoraci\u00f3n de la necesidad de un \ntrasplante hep\u00e1tico, dado que la presencia de un episodio de EH conlleva un mal pron\u00f3stico en la cirrosis.  \nS24216018  \nEl d\u00e9ficit de vitamina D y el s\u00edndrome metab\u00f3lico son 2 entidades muy frecuentes en poblaci\u00f3n espa\u00f1ola. Se ha sugerido que los \npacientes con s\u00edndrome metab\u00f3lico pueden tener d\u00e9ficit de vitamina D con mayor frecuencia que los sujetos sin \u00e9l, y que unos valores \nbajos de vitamina D pueden predisponer al desa rrollo de s\u00edndrome metab\u00f3lico. No obstante, los resultados de estudios prospectivos y \nde intervenci\u00f3n han sido diversos, sin que se haya aclarado por el momento si existe esta relaci\u00f3n. El objetivo de este traba jo fue \nevaluar la relaci\u00f3n entre los valores de 25 -hidroxivitamina D y la prevalencia e incidencia del s\u00edndrome metab\u00f3lico.  \n \nREVISTA ESPA\u00d1OLA DE CARDIOLOGIA  \n \nS24863590  \nLa aparici\u00f3n de los nuevos anticoagulantes orales como tratamiento de prevenci\u00f3n de fen\u00f3menos de tromboembolia en la fibrilac i\u00f3n \nauricular no valvular ha supuesto sin duda un significativo avance. Se ha estudiado la eficacia y la seguridad de los tres nuevos  \nf\u00e1rmacos en ECA de no inferioridad (hip\u00f3tesis principal), en los que tambi\u00e9n se analizaban hip\u00f3tesis de superioridad. Aunque existe un \nl\u00f3gico entusiasmo por conocer qu\u00e9 f\u00e1rmaco es m\u00e1s eficaz, efectivo y eficiente, sin las pertinentes comparaciones directas no se podr\u00e1 \nobtener de manera fiable esa informaci\u00f3n. En todo caso, resulta razonable pensar que, conforme vaya pasando el tiempo  y se tenga \nm\u00e1s datos de estudios observacionales, se ir\u00e1n definiendo las caracter\u00edsticas de la enfermedad \u2014pero, sobre todo, del paciente \n(comorbilidades, riesgo hemorr\u00e1gico, factores psicosociales, etc.) \u2014 y del entorno que definir\u00e1n las indicaciones prec isas de cada \nf\u00e1rmaco para grupos de pacientes concretos.  \nS24863597  \nActualmente est\u00e1 bien establecido que la alta reactividad plaquetaria a la adenosina difosfato durante el tratamiento con clo pidogrel es \nun factor independiente predictivo del riesgo de eve ntos isqu\u00e9micos en pacientes a los que se ha practicado una intervenci\u00f3n coronaria \npercut\u00e1nea. Sin embargo, el papel exacto de las pruebas de la funci\u00f3n plaquetaria sigue siendo objeto de controversia. Las pr uebas de \nla funci\u00f3n plaquetaria para asegurar un a inhibici\u00f3n plaquetaria \u00f3ptima han sido recomendadas por algunos autores para mejorar los \nresultados en los pacientes tratados con clopidogrel. En ensayos prospectivos y aleatorizados recientes sobre tratamiento \nantiagregante plaquetario personalizado, no  se ha podido demostrar un efecto favorable de las pruebas de la funci\u00f3n plaquetaria en \ncuanto a mejora de los resultados cl\u00ednicos. En este art\u00edculo se analizan los mecanismos de la falta de respuesta a clopidogre l, los \nensayos recientes de las pruebas de la funci\u00f3n plaquetaria y otros nuevos avances en el campo del tratamiento antiagregante \nplaquetario personalizado.  \nS24863592  \nEste estudio aporta informaci\u00f3n desde una perspectiva nacional y muestra una prevalencia de factores de riesgo cardiovascular  \nsuper ior en el sur de Espa\u00f1a, con estrecha correlaci\u00f3n con la obesidad, el estilo de vida sedentario e indicadores de una situaci\u00f3 n \nsocioecon\u00f3mica desfavorecida.  \n \nSCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE  \n \nS24914458  \nExperienced GPs seem to better tolerate uncertainty and also seem to fear medical errors less than their young colleagues. Yo ung and \nmore experienced GPs use different coping strategies for dealing with medical errors. Implications. When GPs become more \nexperienced, they seem to get better at coping with medical errors. Means to support these skills should be studied in future r esearch.  \nS24920316  \nGAD is rather common among high utilizers of primary care, although the prevalence of 4% is lower than that pr eviously reported. GAD -\n7 is a valid and useful tool for detecting GAD among primary health care patients.  \nS24779455  \nOGTTh may be a useful screening method for IGT in risk groups such as hypertensive patients.  \nS24931511  \nOverall, patients with a high CV risk were less likely to be prescribed an NSAID for musculoskeletal complaints than patients with a low \nCV risk. Nevertheless, one in five high CV risk patients received an NSAID, indicating that there is still room for improveme nt.  \n \nTHE LANCET  \n \nS24613026  \nThe excess risk of stroke associated with diabetes is significantly higher in women than men, independent of sex differences in other \nmajor cardiovascular risk factors. These data add to the existing evidence that men and women experience diabet es-related diseases \ndifferently and suggest the need for further work to clarify the biological, behavioural, or social mechanisms involved.  \nS24881994  \nThe widely held assumptions that blood pressure has strong associations with the occurrence of all cardi ovascular diseases across a \nwide age range, and that diastolic and systolic associations are concordant, are not supported by the findings of this high -resolution \nstudy. Despite modern treatments, the lifetime burden of hypertension is substantial. These f indings emphasise the need for new blood \npressure -lowering strategies, and will help to inform the design of randomised trials to assess them.  \nS24630777  \nIncreased BMI in adults of European origin is associated with increased methylation at the HIF3A locus  in blood cells and in adipose \ntissue. Our findings suggest that perturbation of hypoxia inducible transcription factor pathways could have an important rol e in the \nresponse to increased weight in people.  \nS24881995  \nIf the same systematic improvement in al l aspects of hypertension management continues until 2022, 80% of patients with treated \nhypertension will have controlled blood pressure levels with a potential annual saving of about 50,000 major cardiovascular e vents.  \nS24881993  \nNebivolol and valsartan f ixed-dose combination is an effective and well -tolerated treatment option for patients with hypertension.  \nS24910231   \n In the past couple of decades, evidence from prospective observational studies and clinical trials has converged to support t he \nimportance of individual nutrients, foods, and dietary patterns in the prevention and management of type 2 diabetes. The quality of \ndietary fats and carbohydrates consumed is more crucial than is the quantity of these macronutrients. Diets rich in wholegrai ns, fruits , \nvegetables, legumes, and nuts; moderate in alcohol consumption; and lower in refined grains, red or processed meats, and suga r-\nsweetened beverages have been shown to reduce the risk of diabetes and improve glycaemic control and blood lipids in patients  with \ndiabetes. With an emphasis on overall diet quality, several dietary patterns such as Mediterranean, low glycaemic index, mode rately low \ncarbohydrate, and vegetarian diets can be tailored to personal and cultural food preferences and appropriate calorie  needs for weight \ncontrol and diabetes prevention and management. Although much progress has been made in development and implementation of \nevidence -based nutrition recommendations in developed countries, concerted worldwide efforts and policies are warran ted to alleviate \nregional disparities.  \n \nTHE NEW ENGLAND JOURNAL OF MEDICINE  \n \nS24795142  \nAmong children with vesicoureteral  reflux after urinary tract infection, antimicrobial prophylaxis was associated with a substantially \nreduced risk of recurrence but not of renal scarring. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases \nand others; RIVUR Cli nicalTrials.gov number, NCT00405704.).  \nS24941178  \nThe results of this large, population -based cohort study suggested no substantial increase in the risk of cardiac malformations \nattributable to antidepressant use during the first trimester. (Funded by the Agency for Healthcare Research and Quality and the \nNational Institutes of Health.).  \nS24918371  \nIn adults with obesity and obstructive sleep apnea, CPAP combined with a weight -loss intervention did not reduce CRP levels more than \neither intervention alone. In secondary analyses, weight loss provided an incremental reduction in insulin resistance and serum \ntriglyceride levels when combined with CPAP. In addition, adherence to a regimen of weight loss and CPAP may result in increm ental \nreductions in blood pres sure as compared with either intervention alone. (Funded by the National Heart, Lung, and Blood Institute; \nClinicalTrials.gov number, NCT0371293 .).  \nS24918372  \nIn patients with cardiovascular disease or multiple cardiovascular risk factors, the treatment o f obstructive sleep apnea with CPAP, but \nnot nocturnal supplemental oxygen, resulted in a significant reduction in blood pressure. (Funded by the National Heart, Lung , and \nBlood Institute and others; HeartBEAT ClinicalTrials.gov number, NCT01086800 .).  \nS24897082  \nOnce -weekly intravenous dalbavancin was not inferior to twice -daily intravenous vancomycin followed by oral linezolid for the treatment \nof acute bacterial skin and skin -structure infection. (Funded by Durata Therapeutics; DISCOVER 1 and DISCOVER 2 ClinicalTrials.gov \nnumbers, NCT01339091 and NCT01431339.).  \nS24896818  \nTreatment with naloxegol, as compared with placebo, resulted in a significantly higher rate of treatment response, without re ducing \nopioid -mediated analgesia. (Funded by AstraZeneca; KOD IAC-04 and KODIAC -05 ClinicalTrials.gov numbers, NCT01309841 and \nNCT01323790, respectively.).  \nS24897083  \nA single dose of oritavancin was noninferior to twice -daily vancomycin  administered for 7 to 10 days for the treatment of acute bacterial \nskin and skin -structure infections caused by gram -positive pathogens. (Funded by the Medicines Company; SOLO I ClinicalTrials.gov \nnumber, NCT01252719.).  \n \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}